Shooting for the StarS

Shooting for theStarSEntering the Dawn of Unprecedented Breakthroughs in Life Sciences & Medicine

18TH ANNUAL CONFERENCE OF THE CHINESE AMERICAN BIOPHARMACEUTICAL SOCIETY

BioPaciffiic Conference 2016 太平洋生物大会18th CABS Annual ConferenceMay 7th, Saturday, 2016, 8:00AM-9:00PMSan Mateo Marriott, 1770 SouthAmphlett Blvd., San Mateo, CA 94402

Platiumn

Gold

BIOPACIFIC CONFERENCE

2016 SPONSORS

Silver

Alliance and Promotional Partners

Diamond

2

CaBS Contact Information

中美药协联系信息

Mailing Address 邮政地址

268 Bush Street, #1888

San Francisco, CA 94104, USA

Website 网页地址

www.cabsweb.org

www.biopacificconference.org

Email 电子邮件信箱

General information

一般信息

[email protected]

Membership 会员申请

[email protected]

Fundraising 募款

[email protected]

Brochure Design

会议手册设计

Xiaojun Li

Brochure Production

会议手册制作

CABS Publication Committee 2016

Our Mission

• To serve biopharmaceutical professionals with interests in China and

promote interactions locally and across the Pacific

为有意在中国创业经商的专业人士提供本地及跨太平洋的合作机会

• To foster business opportunities and exchanges in the life science industry

between the U.S. and China

促进中美生物医药交流和商业合作

• To promote public awareness of progress and development in the

pharmaceutical and biotechnological industry

提高公众对生物技术及制药行业新进展的了解

• To collaborate with other organizations in areas of mutual interest

与其它机构和组织发展互利合作关系

3

4

TABLE OF CONTENTS

2 BioPacific Conference 2016 Sponsors and Partners

3 Our Mission CaBS Contact Information

4 table of Contents

6 CaBS Leadership

7 2016 BioPacific Conference Organizing Committee

8 about CaBS

9 remarks from the President of CaBS

10 CaBS Membership Facts

11 Inaugural BioPacific Partnering Forum

12 BioPacific Conference 2016 agenda

14 Speakers

Gerald Chan, Sc.D.

Hari Kumar, Ph.D.

Piers Whitehead

Robert Lou

Hui Zhang,

Jinqun Yin, MBA

Mark Selby, Ph.D.

Stanley Lei Qi, Ph.D.

Darren Ji, M.D., Ph.D., MBA

Charles Comey, J.D.

Thomas L. Irving, J.D.

Wen Li, Ph.D.

Shawn Qian, Ph.D.

Shooting for the Stars

4

5

Ch inese Amer i can B iopha rmaceu t i ca l Soc i e ty

2 BioPacific Conference 2016 Sponsors and Partners

3 Our Mission CaBS Contact Information

4 table of Contents

6 CaBS Leadership

7 2016 BioPacific Conference Organizing Committee

8 about CaBS

9 remarks from the President of CaBS

10 CaBS Membership Facts

11 Inaugural BioPacific Partnering Forum

12 BioPacific Conference 2016 agenda

14 Speakers

Gerald Chan, Sc.D.

Hari Kumar, Ph.D.

Piers Whitehead

Robert Lou

Hui Zhang,

Jinqun Yin, MBA

Mark Selby, Ph.D.

Stanley Lei Qi, Ph.D.

Darren Ji, M.D., Ph.D., MBA

Charles Comey, J.D.

Thomas L. Irving, J.D.

Wen Li, Ph.D.

Shawn Qian, Ph.D.

Xian-Ping Lu, Ph.D.

Dan Zhang, M.D., Ph.D.

Xiaodong Yang, M.D., Ph.D.

Cheni Kwok, Ph.D., CLP

Connie Sun, Ph.D.

Steven Adams, DVM, Ph.D.

Min Cui, Ph.D.

Alexis Ji, Ph.D., MBA

Shawn Lee, Ph.D.

Cheng Liu, Ph.D.

Vincent Liu, Ph.D.

Yuwen Liu

James Zhao, M.D.

Jennifer Hu, Ph.D.

35 2016 CaBS K. Fong award in Life Sciences

38 CaBS activities 2015 – 2016

Highlight of Past Events with Our Partners

Science & Technology Programs

Business & Career Development

International Collaboration

Social Life

Membership

50 advertisements

63 CaBS Membership/Sponsorship Benefits

*The official working language of the conference is English

B I O P A C I F I C C O N F E R E N C E 2 0 1 6

5

CABS LeadershipBoard of DirectorsAlan Hao, Ph.D.Jing-Shan Hu, Ph.D.Leping Li, Ph.D.Shichang Miao, Ph.D. Zhonghua Pei, Ph.D. Jun Xiang, Ph.D. Janet Xiao, Ph.D., J.D. Naibo Yang, Ph.D. Wentao Zhang, Ph.D.

advisory BoardWei Dong, M.D., Ph.D.Baolu Chen, Ph.D. Keting Chu, M.D., Ph.D. John Wang, Ph.D. Guoliang Yu, Ph.D. Cheng Li, Ph.D.DQ Wang, Ph.D. Yingfei Wei, Ph.D.

2016 Executive Council PresidentJiangwen Majeti, Ph.D., M.B.A. Roche/GenentechPresident-ElectCheni Kwok, Ph.D., CLP, Linear DreamsPast PresidentXiaolin Alan Hao, Ph.D., AIM Biosciences Inc.treasurerDavid Wang, B.S., C.P.A.BookkeeperYao Long, B.S. Epitomics, Inc.

Business & Career DevelopmentCo-chairsJessica Sun, Ph.D. Reset TherapeuticsAlex J. Zhang, Ph.D. Enverest, Inc.Elected MembersTim Tian, Ph.D. CelloBio Inc.appointed Members/VolunteersTing Jia, Ph.D. Jiangsu Hengrui MedicineShenshen Hu, Ph.D. UC Berkeley

FundraisingCo-chairsJianlong Lou, Ph.D. UCSFGavin Lu, Ph.D. Eureka Therapeutics Inc.Elected MembersCharles Chen, Ph.D. Bellen ChemistryNorman Zhou, Ph.D. Genentechappointed Members/VolunteersLi-Ming Liang, Ph.D. Nexcelom Bioscience

International CollaborationCo-chairsYan Wang, Ph.D. Gazelle TechnologiesWei Zhang, Ph.D. Robotic MedsystemsElected MembersDannis Chang, Ph.D. Genentechappointed Members/VolunteersHao Wu, Ph.D. UCSFLingjie Guan, Ph.D. Bayer

MembershipCo-chairsLiping Meng, Ph.D. Gilead SciencesYonghua Pan, Ph.D. Sangamo BiosciencesElected MembersYan Qi, Ph.D. Morrison & Foerster LLPLin Yan, Ph.D. Applied StemCells, Inc.

OperationsChairCarrie Kaiyue Wang, M.D. Concept to ClinicElected MembersZhican Wang, Ph.D. Amgenappointed Members/VolunteersYang Du, Ph.D. Stanford

Publication & CommunicationCo-chairsZhenhai Shen, Ph.D. GenentechYang Tian, Ph.D. Gilead SciencesElected MembersJieyi Wang, Ph.D. AbbvieEva Wang, Ph.D. HTG Molecular DxXiang Wang, Ph.D. Denali Therapeutics

Science & technologyCo-chairsAnn Mongan, Ph.D. Thermo Fisher ScientificJiwen (Jim) Liu, Ph.D. RIFA Pharma, Inc.Elected MembersTaotao Chen, Ph.D. BayerLuqia Hou, Ph.D. Stanford

Social LifeCo-chairsSihong Zhou, Sutro BiopharmaJian (Ken) Zhang, Ph.D. PharmacyclicsElected MembersLynn Guo, Ph.D. Genentech


6

2016 Biopacific Conference Organizing Committee• CheniKwok,Ph.D.,CLP,2016BioPacificConferenceChair;CABSPresident-Elect;ManagingPartner,LinearDreams• JiangwenMajeti,Ph.D.,MBA,PresidentCABS;GlobalCategoryManager,BiomarkerandCDx,Roche/Genentech• CarrieKaiyueWang,M.D.,CABSOperationsChair,Pre-clinical/Toxicology,ConcepttoClinic• Gavin(Jingwei)Lu,Co-ChairCABSFundraisingCommittee;ResearchScientist,EurekaTherapeutics• JianlongLou,Co-Chair,CABSFundraisingCommittee;AssociateProfessor,UCSF• YangTian,Ph.D.,Co-Chair,CABSPublicationCommittee;ResearchScientist,Gilead• ZhenhaiShen,Ph.D.,MBA,Co-ChairCABSPublicationCommittee;Director,ResearchServiceProcurement,GlobalPharma

Procurement, Genentech• LipingMeng,Ph.D.,Co-ChairCABSMembershipCommittee;ResearchScientistGilead• YonghuaPan,Ph.D.,Co-ChairCABSMembershipCommittee;Scientist,SangamoBioSciences• YanWang,Ph.D.,Co-Chair,CABSInternationalCollaborationCommittee;VicePresident,BusinessDevelopment,Gazelle

Technologies• WeiZhang,Ph.D.,Co-Chair,CABSInternationalCollaboration,ProjectManager,HBISolutions• AlexJ.Zhang,Ph.D.,MBA,Co-ChairCABSBusinessandCareerDevelopmentCommittee;ManagingPartner,Enverest• JessicaSun,Ph.D.,Co-ChairCABSBusinessandCareerDevelopmentCommittee;Director,InVivoBiology;ResetTherapeutics• HaoWu,Ph.D.,CABSInternationalCollaborationCommittee,AssociateSpecialist,UCSF• AlexisJi,Ph.D.,MBA,Principal,WuXiHealthcareVentures• ShawnQian,Ph.D.,Co-Founder,ChiefExecutiveOfficer&President,NeuPharma• SihongZhou,Ph.D.Co-ChairCABSSocialLifeCommittee;SutroBiopharma• Jian(Ken)Zhang,Ph.D.Co-ChairCABSSocialLifeCommittee;Pharmacyclics

Special acknowledgements:

• 2015-2016CABSOperations,ExecutiveCommitteesandvolunteers• KenFong,Ph.D.,FounderandChairman,KensonVenturesLLC• WentaoZhang,Ph.D.,CABSBOD,Founder,QuintaraDiscovery• RuhongJiang,Ph.D.,CEO&President,AppliedStemCells• CharleneLiao,Ph.D.,ProjectTeamLeader,Genentech• ShichangMiao,Ph.D.,SeniorDirector,Discovery&ClinicalDrugMetabolism/ Pharmacokinetics at ChemoCentryx Inc.• MohanSrinivasan,Director,ProteinChemistry,Bristol-MyersSquibb• ConnieSun,Ph.D.,SVP,Business&CorporateDevelopment,Pharmaron• MinliXie,Ph.D.,SeniorDirector,Medivation• NaiboYang,Ph.D.,Director,ImmunogeneticsatCompleteGenomicsInc.

Graphics and Websites:• XiaojunLi,GraphicDesign/WebsiteDesign• MichaelLin,WebsiteDesign&Support,PinkTrumpetAssociates


7

About CABSWho We are

The Chinese American Biopharmaceutical Society (CABS) is a non-profit organization for professionals in the

biopharmaceutical industry. CABS is headquartered in San Francisco Bay Area, California. This is the home of

theSiliconValley, thebirthplaceofbiotechnologyandoneofthe largestbiomedicalclusterswiththehighest

venture capital investment in the world. There are more than a thousand biopharmaceutical/biotech companies

in this area, including several large biopharmaceuticals such as Amgen, Genentech and Gilead. CABS is a highly

influential association with more than 3000 members and subscribers in the life sciences industry. About 70% of

our members have Ph.D. degree relating to life sciences. A considerable proportion of the members are holding

senior research and management positions in American and multi-national life sciences corporations. Many of

our members are experts and leaders, innovative entrepreneurs, lawyers and venture capitalists or investors in

the life sciences sector. CABS is the largest and most active Chinese biopharmaceutical association in Northern

America. We organize many activities to promote Sino-US collaborations in life sciences and to provide Science

& Technology Parks and life sciences companies in China with an excellent platform to promote business and

to recruit talent. In addition to year-round technology and business seminars, the annual BioPacific Conference

organized by CABS is a highly anticipated event that attracts hundreds of biopharmaceutical professionals and

business leaders.

CaBS Membership Demographics

Our membership consists of life science professionals from a broad range of experience levels. A large percentage

of our members hold senior or executive positions in the industry, and we are proud to have numerous

entrepreneurs who have successfully started and sold life science companies in our pedigree. In addition, we

continue to attract new talent from the local academic institutions (UC Berkeley, UC San Francisco, and Stanford

University, among others).


8

Welcome to the 2016 BioPacific Conference, the 18th annual conference of the Chinese American Biopharmaceutical Society (CABS)!

I would like to thank President-elect Dr. Cheni Kwok, the conference organization committee, and all the volunteers who have worked diligently for the past six months to bring you this impressive program.

The biopharmaceutical industry has been experiencing tremendous growth in recent years. We have record high FDA new drug approvals, an active IPO market, and exciting Merger and Acquisition activities. Leading in biotech investment from venture capital firms, the San Francisco Bay Area prizes itself not only as a hot bed for innovation and start-ups, but also as a magnet for talent – both of which have increasingly attracted attention from global companies including many in China. Our 18th annual conference will cover multiple aspects of these important trends.

As one of the largest non-profit biopharmaceutical professional organizations on the west coast, CABS is uniquely positioned to ride the wave of biotech/pharmaceutical success. On one hand, we continue to serve our members by providing cutting-edge and educational Science and Technology workshops and nur-turing the growth of next generation professionals with career-mentoring programs. On the other hand, we actively engage companies from China to support their talent recruitment activities and investment inter-ests for novel technologies and pharmaceutical programs. To foster greater exchange between the biotech communities in both the US and China, we continue to organize annual delegation trips to China. Taking advantage of our San Francisco location, we successfully organized the first “CABS Investor Forum 2016” at the JP Morgan conference to bridge an ongoing dialogue between investors and entrepreneurs across the Pacific Ocean.

CABS’s success is a story of a strong community with the support of many. We are honored to announce Dr.GeraldChanasthewinnerofthe2016VisionaryinLifeSciencesCABSK.FongSpecialAward.Dr.Chanhas made life-long contributions in cultivating a generation of successful entrepreneurs and life sciences companies. The spirit of generosity and outstanding leadership embodied by Dr. Chan will transpire CABS and beyond. As the president of CABS, I am extremely proud to work with colleagues in our eight executive committeesandoffices,whosepassionanddedicationmakeCABSabetterorganizationeveryday.Iamalso truly appreciative of our devoted members and sponsors, who have and continue to support CABS.

Thank you for joining us. I hope you enjoy today’s program.

With warm regards,

Jiangwen Majeti, CABS President


9

Overall Membership

LinkedIn MembershipOur LinkedIn Group has also seen continued growth over the last year and is becoming an increasingly important component in our mission of promoting public awareness of the life science industry, encouraging business opportunity and exchange, and serving as a bridge for the life science industry throughout the Asia Pacific.URL:https://www.linkedin.com/grp/home?gid=695127MembershipasofApril20,2016:618

Mem

bership

Others3%

AcademicFaculty

7%Ph.D.

Student/PostDoc

9%

Executives12%

Scientist69%

Ph.D.72%

J.D.5%

MBA5%

Master's13%

Bachelor's5%

By PositionBy Degree

Senior 38%

Entry 19% Director

8%

Manager 8%

Owner 6%

CXO 5%

Other 16%

Biotech 42%

Pharma-ceuticals

18%

Research 14%

Higher Education

3%

Medical Devices

3%

Chemicals 3% Other

17%

By Seniority By Industry

CRO6%

ProfessionalServices

7%

Academic16%

BioPharma-ceutical49%

MedicalDevices,

Instrument&

Diagnostics22%

By FunctionBy Industry

Academic14%

R&D43%

Sales&Marketing

12%

Operations&Manufacturing

15%

VentureCapital

6% Law6%

ManagementConsulting

4%


10

Inaugural BioPacific Partnering ForumThe 2016 BioPacific Conference brings together leaders in the life sciences community from the Pacific Rim and the United States. In order to further facilitate the interactions including project introduction and talent recruitment between our attendees and our sponsors, we are introducing a two-day BioPacific Partnering Forum in conjunction with our conference this year.

Our Sponsors:• Three major sponsors:

•NingboKangtaiboTechnologyDevelopmentCo.Ltd&NingboHangzhouBayNewZone•ZiboNationalHigh-techIndustrialDevelopmentZone•ChengduKanghongPharmaceuticalsGroup

• All sponsors and exhibitors of 2016 BioPacific Conference

How to Participate:• Complimentary for all attendees, sponsors and exhibitors of the 2016 BioPacific Conference• Sign up at [email protected] to schedule one-on-one meetings

•PleaseindicatewhichsponsoryouwouldliketomeetalongwithyourCVandprojectpptasappropriate•Ifyouareinterestedinmeetingothersponsors,pleaseletusknow

When and Where:• May 7 from 9am – 6pm

Onsite at the 2016 BioPacific Conference One-on-one meeting

• May 8 from 10am – 5pm•HanqiInvestmentInc.(1633BayshoreHwy,Burlingame,CA94010)•Featuredpresentationsfromthreemajorsponsors;briefpresentationsfromotherparticipatingsponsors•Followedbyone-on-onemeeting

About the Inaugural BioPacific Partnering Forum:• Enable one-on-one discussions with BioPacific Conference sponsors and exhibitors• Learn more about incentives for entrepreneurs at Ningbo Kangtaibo Technology Development Co. Ltd,

Ningbo Hangzhou Bay New Zone and Zibo National High-tech Industrial Development Zone• Access to senior management of Chengdu Kanghong Pharmaceuticals Group for talent recruitment and

project collaboration

18TH ANNUAL CONFERENCE OF THE CHINESE AMERICAN BIOPHARMACEUTICAL SOCIETY


11

mailto:[email protected]

Shooting for the Stars – Entering the Dawn of Unprecedented Breakthroughs in Life Sciences & Medicine

8:00am – 8:45am Registration

Morning Session I: Welcome & CABS K. Fong Award Session Chair: Wentao Zhang, Ph.D. 8:45am – 8:50am Welcome Remarks Cheni Kwok, Ph.D., CLP, President-Elect of CABS & 2016 BioPacific Conference Organizing Committee Chair

8:50am–9:00am State of the Society Jiangwen Majeti, Ph.D., MBA, President of CABS 9:00am – 9:10am CABS K. Fong Special Award: Visionary in Life Sciences Presenter:KennethFong,Ph.D.,Chairman,KensonVentures Awardee: Gerald Chan, Sc.D., Co-Founder, Morningside 9:10am –10:00am Somewhere Between Science and Humanity Gerald Chan, Sc.D., Co-Founder, Morningside

10:00am -10:20am Break

Morning Session II: Successful Business Models & Entrepreneurship Session Chair: Jessica Sun, M.D. & Gavin Lu, Ph.D. 10:20am–10:55am M&A: An Insider’s Perspective HariKumar,Ph.D.,Ex-ChiefExecutiveOfficer&BoardofDirector,AdheronTherapeutics 10:55am–11:30am Vaccines: Lessons from the Oldest Class of Biologics PiersWhitehead,ExecutiveVicePresident&ChiefBusinessOfficer,PaxVax 11:30am –12:00pm Life Sciences Parks in China: Growth and Trends Robert Lou, Manager Director, Ningbo Kangtaibo Technology Development Co. Ltd & Hui Zhang, Deputy Director, Ningbo Hangzhou Bay New Zone Investments and Partnership Branch

AGENDABIOPACIFIC CONFERENCE 2016


12

Shooting for the Stars – Entering the Dawn of Unprecedented Breakthroughs in Life Sciences & Medicine

12:00pm – 1:00pm Lunch Break

Afternoon Session I: Life Sciences Breakthroughs & Partnerships Session Chairs: Connie Sun, Ph.D. & Charlene Liao Ph.D.

1:00pm – 1:30pm Chengdu Kanghong Biotech Co and Conbercept JinqunYin,MBA,VicePresident,ChengduKanghongPharmaceuticalGroup

1:30pm–2:05pm Immunotherapy: Past, Present and Future Mark Selby, Ph.D., Senior Director, Immuno-oncology, Bristol-Myers Squibb 2:05pm–2:40pm CRISPR/dCas9 Technology for Genome Manipulation and Disease Research Stanley Lei Qi, Ph.D., Assistant Professor, Department of Bioengineering and Department of Chemical and Systems Biology, Stanford University 2:40pm–3:15pm The Art of Partnering DarrenJi,M.D.,Ph.D.,MBA,VicePresidentandGlobalHeadofRochePartnering,AsiaandEmergingMarkets 3:15pm–3:45pm Key Trends and Case Studies: U.S. – China Cross-Border Life Sciences Investment and Strategic Cooperation Charles Comey, J.D., Partner, Morrison & Foerster LLP 3:45pm – 4:05pm Coffee break

Afternoon Session II: Trends in BioPharmaceutical Development – China & Global ConsiderationsSession Chair: Shichang Miao, Ph.D. & Yang Tian, Ph.D. 4:05pm–5:20pm Panel Discussion: BioPharmaceutical Development - China & Global Considerations (Moderator: Shichang Miao, Ph.D.) Xian-PingLu,Ph.D.,ChiefExecutiveOfficer&ChiefScientificOfficer,ChipscreenBiosciences ShawnQian,Ph.D.,Co-Founder,ChiefExecutiveOfficer&President,NeuPharma Xiaodong Yang, M.D., Ph.D., President and CEO, Apexigen DanZhang,M.D.,Ph.D.,Chairman&ChiefExecutiveOfficer,FountainMedicineDevelopmentLtd 5:20pm–5:50pm Claim Construction Before PTAB and the Courts Thomas L. Irving, J.D., Partner & Wen Li Ph.D., Associate, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP 5:50pm–5:55pm Introduction to Medicilon Cheni Kwok, Ph.D., CLP, Senior Consultant, Medicilon and Managing Partner, Linear Dreams 5:55pm–6:00pm Introduction to Pharmaron ConnieSun,Ph.D.,SeniorVicePresident,BusinessandCorporateDevelopment,Pharmaron 6:00pm – 6:45pm Networking Session 6:45pm – 7:15pm Dinner

7:15pm - 7:30pm Burma, the Golden Land. A Photographic Journey in Support of Global Health StevenAdams,DVM,Ph.D.,ExecutiveDirector,Portfolio&OperationsforOncologyResearchWorldwideR&D, Pfizer

Evening Session: US-China Cross-Border Healthcare Investment & EntrepreneurshipSession Chair: Yan Wang, Ph.D.

7:30pm – 9:00pm Panel Discussion: US-China Cross-Border Healthcare Investment & Entrepreneurship (Moderator: Alexis Ji Ph.D., MBA) Min Cui, Ph.D., Founding Partner & Managing Director, Decheng Capital AlexisJi,Ph.D.,MBA,Principal,WuXiHealthcareVentures ShawnLee,Ph.D.,Vice-Chairman,XinbangPharmaceuticals;President&CEO,CPCScientificInc. ChengLiu,Ph.D.,Founder&ChiefExecutiveOfficer,EurekaTherapeutics VincentLiu,Ph.D.,SeniorConsultant,WanbangBioPharmaceutical,ShanghaiFosunPharmaceutical(Group)Co.Ltd. Yuwen Liu, Founding Partner, Bohe Angel Fund James Zhao, M.D., Founding Partner, LYFE Capital DarrenJi,M.D.,Ph.D.,MBA,VicePresidentandGlobalHeadofRochePartnering,AsiaandEmergingMarkets JenniferHu,Ph.D.,VenturePartner,QimingVenturePartners 9:00pm Conference Adjourned * The official working language of the conference is English

8:00am – 8:45am Registration

Morning Session I: Welcome & CABS K. Fong Award Session Chair: Wentao Zhang, Ph.D. 8:45am – 8:50am Welcome Remarks Cheni Kwok, Ph.D., CLP, President-Elect of CABS & 2016 BioPacific Conference Organizing Committee Chair

8:50am–9:00am State of the Society Jiangwen Majeti, Ph.D., MBA, President of CABS 9:00am – 9:10am CABS K. Fong Special Award: Visionary in Life Sciences Presenter:KennethFong,Ph.D.,Chairman,KensonVentures Awardee: Gerald Chan, Sc.D., Co-Founder, Morningside 9:10am –10:00am Somewhere Between Science and Humanity Gerald Chan, Sc.D., Co-Founder, Morningside

10:00am -10:20am Break

Morning Session II: Successful Business Models & Entrepreneurship Session Chair: Jessica Sun, M.D. & Gavin Lu, Ph.D. 10:20am–10:55am M&A: An Insider’s Perspective HariKumar,Ph.D.,Ex-ChiefExecutiveOfficer&BoardofDirector,AdheronTherapeutics 10:55am–11:30am Vaccines: Lessons from the Oldest Class of Biologics PiersWhitehead,ExecutiveVicePresident&ChiefBusinessOfficer,PaxVax 11:30am –12:00pm Life Sciences Parks in China: Growth and Trends Robert Lou, Manager Director, Ningbo Kangtaibo Technology Development Co. Ltd & Hui Zhang, Deputy Director, Ningbo Hangzhou Bay New Zone Investments and Partnership Branch


13

SPEAK

ERS

Bio Gerald Chan is the co-founder of Morningside, a private investment group with venture capital, private equity and property investments.

In the life science sector, Morningside focuses on start-up biotechnology companies founded on novel scientific discoveries. Notable investments in oncology that Gerald led include novel approaches to cancer therapeutics such asoncolyticviruses(BioVex,DNAtrix),cancervaccines(Aduro), modified cytotoxic agents (Nucana) and novel targets for therapeutic intervention (CellCentric, K-Gen, Vigeo).Investmentsintheinfectiousdiseaseareaincludenovel antibiotics (MicuRx, Artugen), prophylactic vaccines (Matrivax) and antivirals (Atea). Other investments cover the therapeuticareasofmetabolicdiseases(CVI),autoimmunediseases (Kezar), CNS disorders (Orthogonal, Synchroneuron, Cognoa), and rare orphan diseases (Stealth, Apellis), as well as molecular diagnostics (ACD), drug delivery (Medtrum, Incarda)andmedicaldevices(ViOptix,Kona,Excera).

Gerald is a member of the advisory boards of the International Society for Stem Cell Research, the New York Academy of Science, Cold Spring Harbor Conferences Asia, Johns Hopkins Nanjing Center, and Columbia University Center for Radiological Research. At Harvard University, he is a member of the Global Advisory Council, the Dean’s Board of Advisors of the Harvard T.H. Chan School of Public Health and the Harvard China Fund. He chairs the Overseers Committee of Morningside College of Chinese University of Hong Kong.

Gerald received his BS and MS degrees in engineering from UCLA, his Master’s degree in medical radiological physics and Doctor of Science degree in radiation biology from Harvard University. He received his post-doctoral training at the Dana-Farber Cancer Institute as a fellow of the Leukemia Society of America. The Chinese University of Hong Kong and the University of Glasgow have conferred on him honorary degrees. He was elected to an honorary fellowship at Wolfson College of Oxford University. In 2012, he was the commencement speaker of the Harvard T.H. Chan School of Public Health.

Somewhere between Science and Humanity

Gerald Chan, Sc.D.Co-founderMorningside Group

Winner of 2016 CaBS K. Fong Special awardVisionary in Life Sciences


14

Abstract: Having led two M & A transactions in the last 4 years, my presentation will look at some of the key factors that influence and ultimately bring about a successful transaction. I will use the two events as case studies and try and provide the audience an understanding of how some of the key decisions that were made help to bring about success. We will also look at some of the learnings from the case studies and these in turn should help the audience navigate their own issues. The presentation will try and provide, as near as possible, a template to a successful transaction.

BioHariKumarisaPharmaceuticalexecutivewithover25yearsof experience in the industry.

Hari started his Pharmaceutical career at Roche, first in basic research, subsequently moving to sales and marketing, lifecycle management and finally to business development. During the period of 1996 through 1999, Hari was the European Marketing Director for Eisai Ltd before returning to Roche in 1999 as Global Head of Transplant Immunosuppressives. He moved to Amira PharmaceuticalsIncin2007asChiefBusinessOfficerandafterAmira’sacquisitionin2011,wasChiefExecutiveOfficerof Panmira Pharmaceuticals LLC for two years. In 2013 Hari becameChiefExecutiveOfficerofAdheronTherapeutics,Inc which he led until the successful acquisition of the company.

In his time, Hari has overseen the launch of the immunosuppressive, CellCept®, the Alzheimer’s drug, Aricept® and gastric ulcer drug, Aciphex®. He was also involved in guiding cross functional teams at Roche for the Transplantation franchise which resulted in the growth of the products in the franchise to achieve billion dollar sales. In his role as lead in-licensing person for inflammation at Roche, he identified and partnered valuable products that have enhanced Roche’s portfolio. He was instrumental in partnerships with Isotechnika, Biotie, Biocryst and Actelion. Experience in almost all aspects of the pharmaceutical industry has given Hari a unique understanding on what makes a successful pharmaceutical business.

At Amira, Hari led the process that resulted in the acquisition by Bristol Myers Squibb in 2011. His second big acquisition came as CEO and Board member of Adheron Therapeutics, Inc, which was bought by Roche. He has now led two acquisitions which have resulted in over a billion dollars in returns to investors.

Having trained as an immunologist at University College London where he completed his PhD under the supervision of Prof N A Mitchison, Hari completed a postdoctoral fellowship at Tufts New England Medical Center in Boston and another fellowship at the Marie Curie Cancer Research Centre in UK.

M&A;anInsider’sPerspective

Hari Kumar, Ph.D.Ex-ChiefExecutiveOfficer&BoardofDirectorAdheron Therapeutics Inc.

SPEAK

ERSB I O P A C I F I C C O N F E R E N C E 2 0 1 6

15

Abstract: Vaccinesareoneoftheoldestmedicalinterventionsandhave had a huge impact on human health, but historically have been something of a backwater for the broader biopharmaceutical industry. What lessons might the vaccine industry have for the sector more broadly? And how does onesmallcompany,PaxVax,intendtocompeteandwininamature industry structure?

BioMr.WhiteheadjoinedPaxVaxinearly2013andbrings20years of experience in the vaccines and biopharmaceutical industries.HepreviouslyservedasVicePresidentofCorporate Development for Paris¬based Neovacs. Prior tothat,hewasVicePresidentofCorporateandBusinessDevelopmentforvaccinecompany,VaxGen.AtVaxGen,he negotiated several important partnerships and led the company’s commercial strategy, resulting in the award of a nearly one billion dollar Project Bioshield Act contract. He also spent 10 years at Mercer Management Consulting, whereheheadedtheSanFranciscoofficeandledmarketing,strategy, and manufacturing projects for clients including

theGlobalAllianceforVaccinesandImmunization(GAVI),UNICEF, and several private¬sector pharmaceutical and biopharmaceutical companies. Mr. Whitehead has published extensively on the vaccine industry and related public policy matters and holds an A.B. from Oriel College, Oxford University, England.

Vaccines:LessonsfromtheOldestClassofBiologics

SPEAK

ERS

Piers WhiteheadExecutiveVicePresident&ChiefBusinessOfficerPaxVax


16

Abstract: Mr Robert Lou will provide a historical prospective of the formation and growth of Chinese life sciences parks, an overview on the distribution of life sciences parks throughout China as well as an analysis of the resources provided by the parks to address the needs of the life sciences industry. Mr Lou’s presentation will also discuss how life sciences parks can further improve their competitive advantages to tailor to the needs of the industry.

中国生物医药科技园区成长和园区建设的思考和探索

演讲者通过对中国生物医药园区的形成背景，中国生物医药行业

及园区的分布特点等对生物医药产业园概况进行介绍和分析，从

医药企业对生物医药园区的需求等角度，对如何提升园区竞争力

进行思考，并提出宁波杭州湾生命科技园关于技术基础设施，服

务体系建设和发展等的理念，希望和与会者进行分享和探索。

BioRobert Lou is the founder and managing director of Ningbo Kangtaibo Technology Development Co.,Ltd, which is constructingandoperatingBioVillage,alifescienceparkwith250,000m3 building area in Ningbo Hangzhou Bay New Zone. In 2010, he founded Hangzhou Honor Investment, an investment company mainly focusing on early stage companies investment in life science field. Before that, he had been engaged in international containerized transportation formorethan10yearsandtourismindustryformorethan5years.

Robert Lou got a bachelor degree majoring in Nuclear Engineering in 1987, and a master degree majoring in Enterprise Management in 1990 from Shanghai Jiaotong University.

Robert Lou is the early investor of Pharmaron.

Presentation title: Life Sciences Parks in China: Growth and Trends

SPEAK

ERS

robert Lou 楼国强Manager Director 总经理Ningbo Kangtaibo Technology Development Co.,Ltd 宁波康泰博科技发展有限公司


17

Abstract: Introduction to Ningbo Hangzhou Bay New ZoneMr Hui Zhang will give an introduction to Ningbo Hangzhou Bay New Zone, highlighting the zone’s key achievements.

有关宁波杭州湾新区:宁波杭州湾新区地处中国经济最发达的长三角地区，于2010年2月23日正式成立。新区是目前中国正在大力推进建设的“一带一路”的重要节点，也是宁波港口经济圈建设的重要组成部分。区内分别设有国家级经济技术开发区和国家级出口加工区。

目前新区初步形成了产业、新城、湿地三大功能板块：制造业区块已建成面积达50平方公里，累计落户工业企业项目435个，投产企业331家，集聚了德国大众、德国博世、荷兰联合利华等13家世界500强企业的投资项目19个。重点发展汽车及其关键零部件、通用航空、生命健康产业、智能电气、高端装备和高性能新材料产业。商务新城区27平方公里正在建设，五年来，大型城市综合体、五星级酒店、高等院校、高等级医院、科技研发孵化基地、城市广场等一批功能性项目相继落户建成。新区还拥有43.5平方公里的湿地休闲区，宁波杭州湾湿地是东亚最大的咸淡水海滩湿地之一。2005年在全球环境基金（GEF）和世界银行支持下启动建设，目前4.3平方公里核心区已建成开放并晋升为国家级湿地公园。

生物医药和大健康产业作为宁波杭州湾新区的主导产业之一。为打造百亿级产值产业集群，宁波杭州湾新区规划10平方公里建设宁波杭州湾国际生命健康产业园。依托复旦大学研究院、科创中

心、通济产业园、博士后科研工作站等平台，围绕生物制药、医疗器械、健康产品、健康休闲等领域，打造成为长三角地区重要的生命健康产业基地。

目前，宁波杭州湾国际生命健康产业园已集聚了康龙化成、双成、麟沣、正力安拓等17家企业。园区将依托高端装备制造和生命健康产业基础，重点引进生物制药、医疗器械和大健康产业企业，包括新药研发服务、医药制造、医疗器械设备生产、健康食品及功能性化妆品生产等项目。

宁波杭州湾国际生命健康产业园对接国际优秀生命健康产业项目的优势十分明显，包括区位及交通优势、土地空间优势、市场优势、人力资源优势、自然环境优势、政策体制优势等。此外，为大力发展生命健康产业，支持生命健康企业的发展，打造国际一流生命健康产业园，宁波杭州湾新区为落户项目制定一对一的支持政策。

BioMr Hui Zhang is the Deputy Director of Ningbo Hangzhou Bay New Zone Investments and Partnership. Mr Zhang supports the Director and is responsible for two branches of industrial investment: First branch and Second Branch (International Investment Branch). Mr Zhang is responsible for promoting international business development for the sectorsincludingautomobileandparts;civilaviation,lifesciences and wellness as well as biopharmaceuticals.

Introduction to Ningbo Hangzhou Bay New Zone

SPEAK

ERS

Hui Zhang 张辉Deputy Director, Investment and Partnership Branch 投资合作局副局长Ningbo Hangzhou Bay New Zone 宁波杭州湾新区


18

Abstract: Located in Chengdu, China, Chengdu Kanghong Biotech Co is one of the 7 subsidiaries of the 20-year-old Chengdu Kanghong Pharmaceutical Group Co. It is a leading biopharmaceutical company in China, which specializes in the discovery, development, manufacture, and marketing of innovative biologics. Its first biologics, Conbercept, is a novel anti-VEGF(VascularEndothelialGrowthFactor)agent.Thisis a recombinant fusion protein. including the domain 2 of VEGFreceptor(VEGFR)-1,domain3and4ofVEGFR-2,plushumanIgGFcfragment.ConbercepthashighVEGFbindingaffinity,isa100%humanizedprotein,andcantargetmultipleVEGFsubtypes,includingVEGF-A,VEGF-BandPIGF.After5clinicaltrialsweresuccessfullyfinished,ConberceptOphthalmic Injection was approved to treat Neovascular Age-Related Macular Degeneration (wet AMD) by the CFDA in December, 2013, and launched in China market in March, 2014. Now other indications in ophthalmology, such as Choroidal Neovascularization Secondary to Pathological Myopia(pmCNV),DiabeticMacularEdema(DME),andRetinalVeinOcclusion(RVO)areunderlate-stageclinicaldevelopment. Conbercept has demonstrated well-tolerated safetyprofileandsuperiorefficacy,andhasbeenwellreceived in the Chinese market. Holding strong global IP protection, Chengdu Kanghong Biotech is actively pursuing expansion of Conbercept into global market. Meanwhile, Chengdu Kanghong Biotech has a strong pipeline in R&D including KH903 for the treatment of different tumors, and KH906 for the treatment of neovascularization corneal diseases.

BioJinqunYin,MBAistheVPofChengduKanghongPharmaceutical Group Co, Ltd and Head of Marketing, Sales, Medical Affairs, Government Affairs, and Enterprise Brand Communication. He is a graduate from Beijing International MBAatPekingUniversityandhas15yearsworkingexperiencein multinational pharmaceutical companies, starting in Johnson & Johnson as a medical representative through regional director in China.

In early 2008, joined Bayer Pharmaceuticals as the director of national antithrombotic business unit, led a team to successfully launch Bayer’s global strategic product Xarelto (Rivaroxaban ) in China and uplifted the classic Bayaspirin to the best in Chinese market. In 2011, led and implemented Bayer’s “Chinese Growth Strategy”, working as the director of emerging market development division. Established new mode of “integral promotion of all products” and expanded salesto4thand5thlinecitiesinChina.AfterConberceptwaslaunched in the market, it broke several records of marketing and sales in Chinese pharmaceutical industry. Due to its excellentprofileofsafetyandefficacyinclinicandgreatcontribution to the community in China, Conbercept was awarded one of the best innovative drugs of clinical value by China Pharmaceutical Innovation and Research Development Association (PhIRDA) and the People Net in China. In the past 10 years, only 3 drugs were selected and awarded from all drugs which were launched in the past 10 years in China.

Chengdu Kanghong Biotech Co and Conbercept

Jinqun YinVicePresidentChengdu Kanghong Pharmaceutical Group Co., Ltd

SPEAK


19

SPEAK

ERS

Abstract: The concept of antibody immunotherapy for cancer originated in the laboratory of Dr. James Allison in a paper published in 1996. It took nearly 20 years to bring antibody drugs to patients and to change the treatment paradigm from chemotherapy to include immunotherapy. While anti-PD-1 and anti-PD-L1 antibodies are leading this revolution by promoting deep and durable responses in various cancers, much is yet to be done to ensure greater response rates and expand the repertoire of responsive malignancies. I will highlight the direction of the pharmaceutical industry to meet this challenge and note learnings from in vivo mouse tumor models. Focusing on antibody therapies, I will highlight new targets and therapies which may make cancer a more manageable disease with more options for patients.

BioI completed my graduate studies in the UCSF laboratory of Dr. William Rutter where I cloned and sequenced the Nerve Growth Factor cDNA. I also determined the mouse NGF genomic organization and studied proteolytic processing of the NGF precursor protein. I completed my post-doctoral research in the laboratory of Dr. Matija Peterlin, also at UCSF. HereIresearchedregulationofHIVLTRtranscriptionfocusingon the TAT transcriptional activator and its interaction with theTARsequenceatthe5’endofHIVtranscripts.ThereafterIjoinedtheVaccinesgroupatChiron,workingwithMichaelHoughtononHCVandthenwithJefferyUlmeronDNAvaccination. In 2001 I left Chiron and joined Alan Korman at Medarex. Here we studied the anti-CTLA-4 antibody, ipilimumab. Later, with other colleagues, we developed the nivolumab anti-PD-1 antibody and several other fully human antibodies for oncology.

Immunotherapy: Past, Present and Future

Mark Selby, Ph.D.Senior Director, Immuno-oncologyBristol-Myers Squibb


20

SPEAK

ERS

Abstract: The bacterial CRISPR/Cas9 system offers an approach for RNA-guided genome manipulation in mammalian cells, useful for interrogating and profiling gene functions. We have developed a versatile non-mutagenic genome manipulation platform based on the nuclease-dead Cas9 (dCas9), named CRISPR interference (CRISPRi), which enables complex orthogonal and inducible transcriptional regulation. Using these orthogonally acting dCas9s, we show that the platform enables robust activation and repression of multiple endogenous genes in the genome. We demonstrate the system allows high-throughput whole-genome screening of gene function, and show its uses for modeling diseases such as cardiomyopathy using human induced pluripotent stem (iPS) cells and iPS-derived cardiomyocytes. We compare the use of CRISPRi and CRISPR for different purpose of gene manipulation, and highlight the interesting features comparing gene regulation to gene editing. Finally, we show the use of dCas9 for other genomic studies including capturing the dynamics of chromosome loci in living mammalian cells. The talk will highlight the development and use of CRISPR and dCas9 for non-editing based genome manipulation and its potential applications.

BioDr. Lei (Stanley) Qi is an assistant professor in the Department of Bioengineering, and of Chemical and Systems Biology. He is also faculty fellow in the interdisciplinary Institute for Chemistry, Engineering, and Medicine for Human Health (ChEM-H). He obtained his Ph.D. in Bioengineering from UC Berkeley, and started his lab as Systems Biology Faculty Fellow at UCSF. He is interested in developing novel technologies for cancer and immunology disease research, and Systems and Synthetic Biology. He is one of the major pioneers in the CRISPR technology for targeted genome engineering in mammalian cells. Different from most developers of the CRISPR tools, he has developed a series of gene regulation and imaging technologies, including CRISPR interference (CRISPRi), CRISPR imaging, and high-throughput CRISPR screening. He also worked in the fields of Synthetic Biology, and developed methods to generate synthetic noncoding RNA regulators of transcription, translation, and as molecular sensor for chemicals and intracellular proteins.

CRISPR/dCas9 technology for genome manipulation and disease research

Stanley Lei Qi, Ph.D.Assistant ProfessorStanford University


21

Abstract: A successful partnering is an art. It takes many components to build one. Solid science, differentiated benefits, trust, story, terms, creativity, right people and timing. All these great elements have to come together in a coherent way to date, to dance and to marry. On this topic Darren shares his experiences and perspectives from both sides as a corporate executive and as a past entrepreneur.

BioDr.DarrenJiiscurrentlyVicePresidentandGlobalHead,Asia and Emerging Markets Partnering, Roche. Darren was previously President and CEO of NPBiosciences, a biotech company based in Singapore. Prior to that Darren founded and served as CEO of PharmaLegacy Laboratories, which is a Shanghai-based Contract Research Organization specializing in preclinical pharmacology services. Darren spent 11 years at the Procter & Gamble Company with progressive responsibilities in drug research and development, and as director of bioscience business development in East Asia.

Darren previously served as a Board Director, and Shanghai regional leader of the BayHelix Group, a global organization of Chinese business leaders in life sciences. Darren obtained hismedialdegreefromChinaMedicalUniversity,China;aPhDfromtheUniversityofSheffield,UK;andanMBAfromUniversity of Chicago, USA.

The Art of Partnering

SPEAK

ERS

Darren Ji, M.D., Ph.D., MBa VicePresidentandGlobalHeadRoche Partnering Asia and Emerging Markets


22

Abstract: Morrison & Foerster Corporate Partner Chuck Comey will overview recent market data on China-US life sciences strategic/VCinvestmentandhighlightinterestingissuesfromatworecentcases,thefirstacorporateVCinvestment/ strategic alliance, the second an acquisition, involving Chinese companies partnering or acquiring U.S. life sciences companies.

BioCharles Comey is an M&A and corporate finance partner in thefirm’sPaloAltooffice.Mr.Comey’spracticeexperienceincludes working on the ground in China and Japan for 16 years. He advises clients on mergers and acquisitions, venture capital and private equity financings, and joint ventures and strategic alliances in the technology, consumer and life sciences sectors.

Mr. Comey is recommended as a leading lawyer by Chambers Global2015(PEexpertbasedabroad–Chinafocus,PEforeignexpert–USfocus),ChambersUSA2014and2015(CaliforniaCorporate/M&A:DealsinAsia),Legal500AsiaPacific2015(CorporateandM&A–ForeignFirms),Legal500US2013,Chambers Asia 2011, IFLR1000 2012, PLC Which lawyer? 2010 and Euromoney’s Expert Guides.

Beginning in 1994, Mr. Comey was seconded by Morrison & Foerster to the legal department of a major Japanese trading company, and thereafter was resident for nine years inMorrison&Foerster’sTokyooffice,wherehespecializedin cross-border mergers and acquisitions and strategic alliances.BeforerelocatingtoSiliconValleyinJuly2010,Mr.Comey opened and served as managing partner of the firm’s Shanghaiofficefrom2003–2010.

Mr. Comey is admitted to practice in California and is a member of the California and American bar associations. He speaks and reads Mandarin

Key Trends and Case Studies: U.S. – China Cross-Border Life Sciences Investment and Strategic Cooperation

SPEAK

ERS

Charles Comey, J.D.Partner Morrison & Foerster


23

Abstract: Tom Irving and Wen Li will discuss how to use fundamentally sound principles to prepare and prosecute a U.S. biopharmaceutical patent application to enhance the chances of obtaining a desired claim construction that is appropriate to business objectives and with a view to preempting potential issues in district court litigation and PTAB proceedings. With the rising tension between the district courts and PTAB standards in claim construction

presenting important claim construction developments for practitioners right now, the take-home message remains to lay the groundwork in the specification (the “single best guide” to the meaning of a claim term) for the desired claim construction(s) to withstand both district court and PTAB challenges and yet also cover the reasonably foreseeable competitive products.

Claim Construction Before PTAB and the Courts

SPEAK

ERS

thomas L. Irving, J.D.PartnerFinnegan, Henderson, Farabow, Garrett & Dunner, LLP

Wen Li, Ph.D.AssociateFinnegan, Henderson, Farabow, Garrett & Dunner, LLP


24

Bio of Thomas L. IrvingTom Irving has more than 40 years of experience in the field of intellectual property law. His practice includes America Invents Act (AIA) post-grant proceedings, due diligence, counseling, patent prosecution, and reissue and reexamination. He counsels clients on a wide range of mainly pharmaceutical matters, including pre-litigation, Orange Book listings of patents covering FDA approved drugs, infringement issues, enforceability and validity analysis, and litigation. A significant portion of Mr. Irving’s current practice is focused on AIA post-grant proceedings, including how to enhance the strength of patents in the pharmaceutical space to protect against post-grant challenges. He has served as lead counsel in numerous patent interferences, reissues, andreexaminations;ascounselinnumerousAIApost-grantproceedings;andasanexpertwitnessinpatentlitigation.

Mr. Irving has been involved in every facet of several U.S. district court litigations, thus enhancing his ability to render advice in due diligence, enforceability, infringement, validity, and patent prosecution areas. Mr. Irving has served formorethan25yearsasprincipalteacherofthePatentResources Group (PRG) Chemical Patent Practice course, a comprehensive U.S. chemical patent law course taught two times a year, and he coauthors the multi-volume treatise used in the course. In addition, Mr. Irving originated PRG’s Orange Book and Due Diligence courses, which help prepare patent owners, through effective application drafting and prosecution, to withstand the rigors of AIA’s inter partes review (IPR) and post-grant review (PGR). He presents analyses of U.S. Court of Appeals for the Federal Circuit patent decisions for many state bar association groups and has spoken at numerous national bar association meetings such as the American Intellectual Property Law Association (AIPLA), Intellectual Property Owners Association, and American Bar Association. Mr. Irving has lectured at many law schools in both the United States and China. He also has lectured at the Cold Spring Harbor National Laboratory graduate school, the PatentOfficeoftheStateIntellectualPropertyOffice(SIPO)ofthePeople’sRepublicofChina,andhaspresentednearly50Strafford Webinars on patent law topics, including a number that deal with AIA’s post-grant proceedings. Outside of the patent law field, he has been involved in public health and safety issues related to the preparation of Citizen Petitions before the FDA for pharmaceutical matters.

SPEAK

ERS

Bio of Wen LiWen Li focuses her practice on U.S. and international patent prosecution in the pharmaceutical and chemical areas. Her experience includes managing world-wide patent portfolios for important pharmaceutical companies. Her practice also includes patent litigation, due diligence investigations, patentability/infringement opinion drafting, and client counseling.

Dr. Li has an extensive scientific background and experience in pharmaceutical research. Before joining the firm, she worked for a number of years as a senior/principal medicinal chemist in a biopharmaceutical company where she gained experience in designing and synthesizing small molecule antagonists for GPCRs and Integrin receptors. Dr. Li was a named inventor in several patents in these fields. In addition to having an in-depth understanding of pharmaceutical chemistry, she also has a deep understanding of concepts concerning bioavailability, which include Cmax, AUC, and ADME. She applies her background by working with expert witnesses, particularly in areas involving XRPD, HPLC, and NMR.

Dr. Li’s research background includes synthesis of unnatural amino acids and macrocyclics, as well as the study of secondary structures of peptidomimetics. Dr. Li is also familiar with a wide range of chemistry principles, which include physical chemistry, peptide chemistry, polymer chemistry, and transition-metal catalysis chemistry.


25

BioDr. Shawn Qian is a Co-Founder, President & CEO at NeuPharma, a biopharmaceutical company dedicated to the research and development of innovative medicines for unmet medical needs. Before co-founding NeuPharma, Dr. Qian was an Associate Director of Medicinal Chemistry and Program Leader at Cytokinetics, where he was responsible for the medicinal chemistry efforts on the discovery of novel therapeutics for the treatment of cancer, asthma and cardiovascular diseases. Prior to joining Cytokinetics, Dr. Qian was a NSERC post-doctoral fellow at Harvard University. Dr. Qian received his Ph.D. in Organic Chemistry from University of Alberta, Canada in 2000, and B.Sc. in Chemistry from Nanjing University, China in 1993. He is an author of 42 papers and an inventor of over50patents.

BioDr. Xian-Ping Lu founded Chipscreen Biosciences, the leading drug discovery and development company in China focusing on innovative small molecular therapeutics,15yearsagowithagroupofUS-trainedprofessionals.Previouslyhe was Director of Research at Galderma R&D (subsidiary of L’Oreal and Nestle) in Princeton until 2000, the year he became visiting professor at China’s State Key Laboratory for Biomembrane and Membrane Biotechnology in Tsinghua University. He also participated in founding Galderma Research Inc. and Maxia Pharmaceuticals.

Dr. Lu came to the US in 1989 for postgraduate fellowship study at the Department of Pharmacology, University of California in San Diego, followed by research at La Jolla Cancer Research Foundation (Burnham Institute). He obtained his Ph.D. in Molecular Biology and M.S. in Biochemistry from Peking Union Medical College, Chinese Academy of Medical Sciences, and his B.S. degree in Biochemistry from Sichuan University.

With over 20 years of biomedical research and biotech/pharmaceutical experiences in various therapeutic areas, Dr. Lu is a skilled leader of diverse groups in global operating settings. He has published more than 80 peer-reviewed papers in prestigious journals including Nature and Science. He is the lead inventor of over 80 patented inventions in areas of small molecule therapeutics.

Panel Discussion: BioPharmaceutical Development - China & Global Considerations

SPEAK

ERS

Shawn Qian, Ph.D.Co-Founder,ChiefExecutiveOfficer& President, NeuPharma

Xian-Ping Lu, Ph.D.ChiefExecutiveOfficer&ChiefScientificOfficerChipscreen Biosciences


26

BioDr.DanZhanghasmorethan15yearofdrugdevelopmentexperience.HeistheChairman and CEO of Fountain Medical Development Ltd, a full-service clinical CRO with operations in South East Asia, China, Armenia and USA. With 400 employees,FMDrunsphaseI/II/III/IVoperationswithfullsupportofregulatoryaffairs, data management and biostatistics, EDC and pharmacoeconomics operations.FMDhas70employeesinPhiladelphiaofUSAandhavefiled15NDAsin last 2 years and obtained approval for 10 NDA applications.

Previously, Dr. Zhang was the Head of Clinical Development and Global Safety Assessment at Sigma-Tau Research Inc, Dr. Dan Zhang was a vice president at the Quintiles Transnational Corp., a member of Quintiles Executive Operation Committee, and was also the Chairman of the Board, Quintiles Medical Development (Shanghai) Company Ltd., Before joining Quintiles, Dr. Zhang provided consulting services to many pharmaceutical, medical device and health insurance companies, such as Eli Lilly and Company, Pharmacia & Upjohn, Inc., Medtronic, Inc., and CIGNA Health Care, etc.

Overlastthe15years,Dr.Zhanghasprovidedservicesforthegovernmentandacademic institutions in China. He is a member of grant review committee for National Key Drug Development Fund jointly managed by the Ministry of Science & Technology (MOST) and the National Health and Family Planning Commission of China (NHFPC). He chaired the Bayhelix’ CFDA working committee and works with the agency on the development of technical guidelines. He was a member of the Overseas Expert Committee on New Drug R&D from MOST. He is the senior consultant to Chinese Academy of Medical Sciences and Peking Union Medical College. He was also a visiting professor at the Harbin Medical University of China, Nankai University and Science and Technology University of South China. He is currently a senior consultant to Chinese Academy of Medical Sciences/Peking Union Medical College. Dr. Zhang was an Executive Director of Sino-American Professional Pharmaceutical Society (SAPA). He was the President (2006~2007), Chinese Biopharmaceutical Association-USA (CBA), and a board of director of Bayhelix. He is the Secretary-General of the Association of Thousand Talents Program.

Dr. Zhang received his pre-med training from Peking University and received his M.D. from Peking Union Medical College. He continued his study at the Harvard School of Public Health and received an MPH in health policy and management. Then he continued his training at the Wharton Business School of the University of Pennsylvania, where he obtained his master’s degree in healthcare management in 1998 and is working on his Ph.D. dissertation in the field of health economics and finance.

Dan Zhang, M.D., Ph.D.Chairman&ChiefExecutiveOfficerFountain Medicine Development Ltd

SPEAK


27

BioXiaodongYang,MD,PhD,isPresidentandChiefExecutiveOfficeratApexigen.Xiaodong spent two plus decades in drug discovery and development in the industry, focusing on antibody and oligonucleotide therapeutics. Prior to joining Apexigen,hewasVicePresidentofResearchandPreclinicalDevelopmentatIntradigm Corporation which was acquired by Silence Therapeutics. In this role, he was responsible for overseeing the progress of company’s discovery and preclinical development of RNAi-based therapeutics. Xiaodong began his career as a founding scientist at Abgenix (acquired by Amgen) where he was Senior Director and the head of the Oncology Therapeutic Program Team responsible for setting strategy and managing the company’s oncology portfolio. He played a key role in discovery,developmentandBLAapprovalforVectibix®.Hewasalsoinchargeofthe company’s partnerships on a number of therapeutic antibody collaboration programs. Xiaodong received MD from Beijing Medical University and his PhD from University of Bern. He trained at Stanford University School of Medicine and Novartis.

Introduction to MedicilonMedicilon offers fully integrated pharmaceutical services for the global scientific community. We focus on providing an exceptional client-centered experience and advancing the drug discovery process. Medicilon has been recognized as one of the top drug discovery contract research organizations (CRO) in China and is managed by a team of scientists with a wealth of experience in US-based pharmaceutical and biotechnology companies.

My talk will provide an executive overview of Medicilon’s integrated services across biology, chemistry and preclinical services which are designed to help clients developing their research and discovery programs from the initial idea stage to the IND filing phase.

BioCheni Kwok, Ph.D., CLP is the Senior Consultant of Shanghai Medicilon and the Managing Partner of Linear Dreams LLC, a management consultancy and valuation software firm specialized on corporate strategy, business/corporate development, portfolio analysis and valuation services for the life science industry. She has a broad range of operational expertise and established over 100 transactions including M&A, strategic partnerships, licensing, divestitures, spin-offs and project financing.

AsSeniorVicePresident,CorporateDevelopmentatPoniardPharmaceuticalsInc., Dr. Kwok established corporate and business development, strategic and commercial planning, new product planning, competitive intelligence and

Xiaodong Yang, M.D., Ph.D.President and CEO,Apexigen

Cheni Kwok, Ph.D., CLPSenior Consultant, Medicilon & Managing Partner, Linear Dreams

SPEAK

ERS


28

SPEAK

ERS

forecasting functions. Previously, she was Director of Business Development at Celera Genomics Inc., where she led the business development efforts for Celera’s small molecule therapeutics, including the divestiture of the oncology pipeline (including Imbruvica®(ibrutinib)) to Pharmacyclics Inc.. Dr. Kwok held business development positions of increasing responsibility at Exelixis Inc., where she initiated multiple partnerships and served as the alliance manager for the GlaxoSmithKline PLC (GSK) collaboration. Prior to joining Exelixis Inc., she held various research management, technology assessment and alliance management roles at SmithKline Beecham PLC (now Glaxo SmithKline).

Dr. Kwok received a bachelor’s degree in biotechnology from the Imperial College of Science, Technology and Medicine, University of London, UK, a Ph.D. in human molecular genetics from the University of Cambridge, UK and has earned the Certified Licensing Professional (CLP) credential awarded by the Licensing Executives Society. Dr. Kwok currently serves as the Chair of the American Cancer Society’s California Chinese Unit, President-Elect of the Chinese-American Biopharmaceutical Society (CABS) and Board of Directors of the Chinese Bioscience Association (CBA).

Introduction to PhamaronPharmaron is a premier R&D service provider for the pharmaceutical industry. Pharmaron’s mission is to provide the highest quality R&D services while helping our customers advance their projects in a timely and cost effective manner. Founded in 2003, Pharmaron has invested in our people and our facilities, enabling us to provide high quality R&D service across a number of disciplines including chemistry, biology, DMPK, pharmacology, toxicology and chemical development. Pharmaron has grown steadily to meet the needs of our customers. With over 3,000 employees and operations in China, U.S. and United Kingdom, Pharmaron delivers superior scientific services while maintaining close communication with our customers. Our current clients include small and large pharmaceutical companies in North America, Europe, Japan and China.

BioConnieisSeniorVicePresidentofBusiness&CorporateDevelopment.Sheisresponsible for cross functional business & corporate development, partnership alliance management, and program management.

Prior to joining Pharmaron, she has 16-year drug discovery and development experiences(authorof35publicationsandinventorof47patents)atBiotech/Pharma. She is an inventor of Sutent® currently marketed by Pfizer. Her previous employments include head of Chemistry at Poniard Pharmaceuticals, Sr. Director at AGY Therapeutics Inc., and Director of Chemistry at Pfizer (SUGEN).

Connie holds a Ph.D. in Medicinal Chemistry from University of North Carolina, Chapel Hill, North Carolina. Her postdoc training was at Parke-Davis, Warner-Lambert (later Pfizer), Ann Arbor, MI.

Connie Sun, Ph.D. SeniorVicePresidentofBusiness&Corporate DevelopmentPharmaron


29

Steven adams, DVM, Ph.D.Executive Director of Portfolio & Operations for the Oncology Research in Pfizer Worldwide R&D

SPEAK

ERS

Abstract: “I was originally drawn to Myanmar to capture iconic photographic images of a culture largely unchanged for morethan50years.Duringmyfirstvisitinearly2015,Iwasfortunate to identify a unique opportunity to impact the health of children in a country with one of the poorest health care systems in the world (Ranked #190/190 by World Health Organization). Later that same year, I launched Project Kalay.” Steven AdamsDVM,PhD. The Naga Hlainggu monastery in Yangon, Myanmar cares for more than 1400 orphaned boys and girls. While these children can come from anywhere in Myanmar, a large percentage originates from areas plagued by armed conflict, smuggling, drug trade, and humantrafficking.Sincethisorphanageis also a monastery, it relies exclusively on private donations for all of its support.

While the health care needs of the children at this orphanage are vast, Dr. Adams has focused the efforts of Project Kalay on the most fundamental and basic delivery of hygiene. Our primary goal is to provide hygiene and health education and a steady supply of hand soap in the underserved monastic orphanages in Myanmar. Our first orphanage is the Naga Hlainggu monastery in Yangon, but we hope to eventually extend our efforts to other similarly needy orphanages.

Hand washing with soap is a proven means of delivering highly cost-effective disease prevention. The global private-public organization “Partnership for Hand Washing” estimates aninvestmentofUS$3.35inhandwashingpromotionisestimated to deliver the same amount of health benefit as a US$11 investment in latrine construction, or an investment of many thousands of US dollars in immunizations. Schools provide a critical learning environment for children as well as a vehicle to initiate long-term change in the community.

BioSteven Adams is Executive Director of Portfolio and Operations for Oncology Research at Pfizer Worldwide R&D. In addition to his career as a veterinarian and scientist, he is an avid traveller and photographer. He offers his photographic work for sale as fine art prints and donates all profit to support Project Kalay (see swadamsphoto.com). For further information on Project Kalay see www.projectkalay.org.

Burma, the Golden Land. A Photographic Journey in Support of Global Health


30

SPEAK

ERS

BioDr. Min Cui is the Founding Partner and Managing Director of Decheng Capital. Prior to founding Decheng Capital in 2011, Dr. Cui was an Investment Partner at Bay City Capital, a leading international life science venture capital firm, and focused on evaluating investment opportunities as well as its initiatives in China. Dr. Cui was previously Director of Strategic Investment for the Southern Research Institute, an organization that discovered and developed six anti-cancer drugs approved by the US Food and Drug Administration. Prior to that, Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals. He servedastheChiefScientificOfficerandExecutiveVicePresidentofPanPacificPharmaceuticalsfrom1998to2002andChiefExecutiveOfficerandPresidentofHuconBiopharmaceuticalsfrom2003to2005,respectively.Inthesepositions,heled efforts in discovery and development of several key technologies in the fields of oncology, cardiology, infectious and inflammatory diseases. Dr. Cui is a member of the board of directors of GenapSys, GeneWeave Biosciences (acquired by Roche for$425M),KetaiMedical,ShenzhenGeneMDxBiotechnology,AccuragenandSinomed. His investment portfolio also includes Ion Torrent Systems (acquired by LifeTechnologiesfor$725M),GenturaDx(acquiredbyLuminex),ChinaBiologicProducts (NASDAQ: CBPO), Epizyme (NASDAQ: EPZM), and Sunesis (NASDAQ: SNSS). Dr. Cui was also a co-founder of CNetwork, a San Francisco based non-profit organization dedicated to serving Chinese communities in North America. He received his PhD in Cancer Biology from Stanford University, and his BS in Molecular Biology from Peking University.

Min Cui, Ph.D. Founding Partner & Managing Director Decheng Capital

Panel Discussion: US-China Cross-Border Healthcare Investment & Entrepreneurship

BioAlexisJijoinedWuXiHealthcareVenturesasaprincipalin2014.Shebrings12 years of research, product development and investing experience in the biotechnologyindustry.AtWuXiVentures,sheisresponsibleforevaluatingand investing in early-stage companies in the US, focusing on opportunities in therapeutics, devices, diagnostics, and healthcare IT. Before joining WuXi, AlexisworkedatARCHVenturePartnersonlifescienceventureinvestment.Alexis started her career in senior scientist positions at Merck, Roche, and Life Technologies, with rich experience in drug discovery and development, molecular diagnostics, and genomics. Alexis holds a PhD in Molecular Genetics from Washington University in St. Louis and an MBA from University of Chicago Booth School of Business.

alexis Yongmei Ji, Ph.D., MBaPrincipalWuXiHealthcareVentures


31

BioDr. Shawn Lee serves as vice-Chairman of Xinbang Pharmaceutical (Stock# 002390). Xinbang is a Healthcare company operating in Pharmaceuticals, Hospitals, Biotech services and Medical devices. He founded Chinese Peptide Company (CPC Hangzhou) in 2001 and currently serves as its Chairman of the Board. It is the first peptide CRO out of China and premier peptide CRO/CMO in the world today. CPC’s 210,000 sf cGMP facilities have passed many successful inspections, CFDA and US FDA. Among its several hundred clients are top twenty pharmaceutical companies, innovative biotech companies and renowned scientific institutions. Peptide drugs/devices CPC supported have gained approvalsinChina,SingaporeandEurope.ManyofCPC’sIVD/POCTdeviceshave510KandclearwaivestatuswithinFDA.Hehassubstantialexperienceinentrepreneurship, corporate finance, technology transfer, licensing and business development.Dr.LeealsoservesasCEOofCPCScientificInc,aSiliconValleycompanyhefoundedin2005.HeisactivelysupportingotherstartupcompaniesaspartnerofSVCAngel,HaibangVenture.Shawn Lee, Ph.D.

President and CEOCPC Scientific Inc.

SPEAK

ERS

BioDr. Cheng Liu is the founder and CEO of Eureka Therapeutics, a California company dedicated to development of innovative cancer immunotherapy. Dr. Liu worked at Chiron (now Novartis), where he championed development of first-in-class therapeutic antibody against CSF-1, a key immune regulator, for cancer metastasis treatment. He has multiple issued US and international patents and scientific publications, including in journals of Science and Nature, in the area of therapeutic antibody discovery and engineering. In 2007, he was awarded Special US Congressional Recognition for his contributions to improving human health. Dr. Liu received his B.S. in Cell Biology and Genetics from Beijing University and a Ph.D. in Molecular Cell Biology from the University of California, Berkeley.

Cheng Liu, Ph.D.Founder&ChiefExecutiveOfficerEureka Therapeutics


32

BioDr.LiujoinedWanbangBiopharm,aFosunPharmasubsidiaryin2015toleaditsUS business development effort. Recently he closed a deal to license two small molecule drugs from Rockwell Medical in a transaction of total $39m for upfront plus milestone payments. Currently Dr. Liu is focused on helping Wanbang and Fosun Pharma to acquire more product and technology for the Chinese market. Dr. Liu worked in International Business Division of Fosun Pharma Group from 2009to2015.HisworkcoversFosunPharma’sinvestmentandM&Astrategiesin the North America region. Upon joining the company, Dr. Liu has made significant contribution to implanting Fosun Pharma’s international strategies. His achievements including helping making a $40m investment in an innovated healthcareservicecompanyinNJ,raisinga$500millionprivateequityfundfromoverseaandsettinguptwoJVswithlargeUSandCanadiancompaniesinChina.Before joining Fosun Pharma, he served in several Chinese and US startup companiesaswellasahealthcarefocusedPE/VCfund.

Dr. Liu received his Ph.D. degree in Molecular Biology in Drexel University and MBA degree from University of Rochester.

Vincent Liu, Ph.D.Senior ConsultantWanbang BioPharmaceutical, Shanghai Fosun Pharmaceutical (Group) Co. Ltd.

SPEAK

ERS

BioFounding Partner of Bohe Angel Fund, a 200M RMB fund jointly invested by Wuxi Apptec, Hengrui, Simcere, TigerMed and BGI,etc. Before she set up this angel fund, she was Executive Director of Suzhou Industrial Park Biotech Development Co. Ltd. (BioBAY) and chairwoman & CEO for 9 years. WhenshewasalsoInvestmentCommitteeMemberforBioVENTUREandBoardDirector of Innovent, Admera, Chiral Quest, GenePharma, Reproposing and BrightGene, and Chairwoman of Qiagen (Suzhou) Translational Medicine and Suzhou BioTOP Biotech.

ShejoinedthecompanyasEVPin2005,wasinstrumentalinbuildingBioBAYto be one of the fastest growing biotech clusters serving ~400 biotech startup companies.

She started her career as QA Engineer for Capsugel in 1997, then moved up to QC manager, QA/QC manager and BD manager until she joined Perrigo as first China Chief Representative in 2003.

Yuwen graduated from China Pharmaceutical University with master degree in Pharmaceutics and Master of Management at Fudan University and Norwegian Management School BI, and is a licensed pharmacist.

Yuwen LiuFounding PartnerBohe Angel Fund


33

BioJames Zhao MBA M.D. is a Founding Partner at LYFE Capital and focuses on investment in pharmaceutical, medical device, diagnostic, and animal health at ourShanghaioffice.PriortoestablishingLYFECapital,Jameshasmorethantenyears of experience in investment in China. His previous investments include Jingfeng (SZ:000908),Shanghai Hile(SHA:603718.SS),Changchun Changshen and etc.

After the establishment of LYFE Capital, James has helped a domestic dental company successfully license in an orthodontic technology from USA, as well as build up the partnership between the dental company and a Swiss based company in dental implant sector. In addition, James has helped another domestic company build up partnership with one San Francisco based company andgetthe510Kapprovedproductlicense-intoChina.

A wealth of project experience has been accumulated from his constant internationalengagementsandVentureCapital/growthstageinvestment,andJames also gained abundant knowledge in investment, operations, strategy, cross border business development, sales/marketing and executive placement.James received his Medical Degree from West China University of Medical Sciences,M.S.inMolecularBiologyfromVrijeUniversityinBrussels,andM.B.A.from Washington University, St. Louis.

James Zhao, M.D.Founding PartnerLYFE Capital

SPEAK

ERS

BioDr.Jing-ShanHujoinedQimingVenturePartnersasaVenturePartnerinMarch2016 with the focus on investment in healthcare companies in the US. She brings extensive experience in partnering, licensing, business development, R&D and management from three multinational pharmaceutical companies & two US biotech companies. Before Qiming, she was at Bayer Healthcare Pharmaceuticals asVPandHeadof(External)InnovationCenterChina,responsibleforbuildingpartnerships for Global Drug Discovery with organizations in Greater China. Prior to that, she was Director at Merck & Co (MSD), heading early stage partnering/licensing activities in Greater China for Worldwide Licensing & External Research on novel drug candidates and technologies. She worked previously at Roche Palo Alto as Head of Functional Biology, at Affymetrix as Program Manager of Pharmacogenomics, and at Human Genome Sciences as Scientist of Protein Therapeutics&VEGF-2ProjectLeader.Whileworkingatbiotechcompanies,shehas been successful in partnering with various organizations, including biotech industry and academia such as Stanford University. Dr. Hu obtained her post-doctoral training at Harvard Medical School, PhD degree from Univ. of Texas Graduate School of Biomedical Sciences at MD Anderson Cancer Center, and BS degree in Biochemistry from Peking Univ.

Jennifer Hu, Ph.D.VenturePartnerQimingVenturePartnersUS


34

Chinese-American Biopharmaceutical Society (CABS) K. Fong Award Committee is very pleased to announce that Dr. Gerald Chan is the winner of its CABS K. FongSpecialAward-VisionaryinLifeSciencesforhisextraordinaryvisionand leadership in cultivating a generation of successful entrepreneurs and life sciences companies. Dr. Gerald Chan will be presented with this special award and we are honored that Dr. Chan will also be speaking at the 2016 BioPacific Conference (18th Annual Meeting of CABS) on 7th May 2016 at the San Mateo Marriott San Francisco Airport, 1770 South Amplett Blvd., San Mateo, CA 94402.

Dr. Gerald Chan is the co-founder of Morningside, a private investment group with venture capital, private equity and property investments. In the life science sector, Morningside focuses on start-up biotechnology companies founded on novel scientific discoveries. Notable investments in oncology that Gerald led include novel approaches to cancer therapeutics such as oncolytic viruses(BioVex,DNAtrix),cancervaccines(Aduro),modifiedcytotoxicagents(Nucana) and novel targets for therapeutic intervention (CellCentric, K-Gen, Vigeo).Investmentsintheinfectiousdiseaseareaincludenovelantibiotics(MicuRx, Artugen), prophylactic vaccines (Matrivax) and antivirals (Atea). Otherinvestmentscoverthetherapeuticareasofmetabolicdiseases(CVI),

autoimmune diseases (Kezar), CNS disorders (Orthogonal, Synchroneuron, Cognoa), and rare orphan diseases (Stealth, Apellis),aswellasmoleculardiagnostics(ACD),drugdelivery(Medtrum,Incarda)andmedicaldevices(ViOptix,Kona,Excera). Gerald is a member of the advisory boards of the International Society for Stem Cell Research, the New York Academy of Science, Cold Spring Harbor Conferences Asia, Johns Hopkins Nanjing Center, and Columbia University Center for Radiological Research. At Harvard University, he is a member of the Global Advisory Council, the Dean’s Board of Advisors of the Harvard T.H. Chan School of Public Health and the Harvard China Fund. He chairs the Overseers Committee of Morningside College of Chinese University of Hong Kong.

Gerald received his BS and MS degrees in engineering from UCLA, his Master’s degree in medical radiological physics and Doctor of Science degree in radiation biology from Harvard University. He received his post-doctoral training at the Dana-Farber Cancer Institute as a fellow of the Leukemia Society of America. The Chinese University of Hong Kong and the University of Glasgow have conferred on him honorary degrees. He was elected to an honorary fellowship at Wolfson College of Oxford University. In 2012, he was the commencement speaker of the Harvard T.H. Chan School of Public Health.

“CABS is very proud to honor Dr. Gerald Chan for his life-time contribution in the field of life sciences, his significant achievement towards nurturing a new generation of innovative life sciences companies and his generous support of life scienceseducation,includingatransformativegiftof$350MtotheHarvardSchoolofPublicHealth,thelargestdonationin the 380-year history of the university.” said Dr. Jiangwen Majeti, President of CABS. “We are very grateful to Dr. Ken Fong for his generous long-term support of this award as well as other activities at CABS throughout the year.”

Chinese-American Biopharmaceutical Society (CABS)

K. Fong Special AwardDr. Gerald Chan to be Honored with CABS K. Fong Special Award - Visionary in Life Sciences


35

About CABS K. Fong Award in Life Sciences:CABS K. Fong Award in Life Sciences is presented annually to

recognize those individuals who make significant contributions

in life sciences and biopharmaceutical industry including

outstanding scientific findings, recognized efforts in promoting

life science education and initiatives in improving life science

community, and those who bring therapeutic breakthroughs to

the market and improve healthcare and quality of life. Candidates

must be nominated by an active member of CABS followed by

review and approval of the Selection Committee. Selection criteria

will be based on candidate’s accomplishments in life sciences and

contribution to the life science community, including one or all of

the following:

•Provenachievementsintherapeuticbreakthroughs(including

discovery, process or clinical development), diagnostics or the

research reagent/equipment markets.

•Significantcontributiontothepromotionofacademicand

industrial R&D in biomedical sciences and applications.

•SignificantcontributiontothegeneralbiomedicalandtheCABS

community and to promoting international collaboration in life

sciences.

C A B S

K. Fong Award in LifeSciences


36

About Dr. Kenneth Fong:Dr. Kenneth Fong is currently the founder and chairman ofKensonVentures,LLC,acompanythatspecializesincrafting development strategy for early and mid-stage stage biotech companies. Under his leadership, companies that were acquired or went public between 2007 and 2012 are: SA Biosciences (to Qiagen), DHI (to Quidel), Fermenta (to ThermoFisher), Panomics (to Affymetrix), Epitomics (to Abcam), Bioform (IPO) and Optimer (IPO). Currently, he sitsontheboardsof5biotechcompanies,includingtwobiopharmaceutical, one diagnostic and two research tool company. Prior to Kenson, Ken founded and served as CEO of Clontech Laboratories (1984-1999), which was acquired by Becton Dickinson in 1999. Clontech, a leader in the life science market, was also the largest of its kind founded by anAsianAmerican(400people,including65PhDscientists)during the early years of the biotech industry. Ken served as president of Society of Chinese Bioscientists in North America(~2,000members,2005-09)andPresidentoftheBay Area AAMA (1987). He was a member of the Board of Trustees of California State University (2006-2013), Board of Associates at the Whitehead Biomedical Institute at MIT and a member of the Committee of 100 (US). Ken has many other philanthropic interests. He was one of the lead supporters for the San Jose Tech Museum, the Chinese Historical Society in San Francisco, the Bioengineering Auditorium at UC San Diego and the Indiana University graduate Seminar Programs. He has provided Translational Science Awards through an endowed fund to the San Francisco State University. In addition, he has provided a number of scholarships to Peking University and the CSU students (Kenneth Fong–Hearst endowed Scholarships). In 2006, he was also involved in establishing the Fong Optometry and Medical Library at UC Berkeley and more recently an endowed professorship to Stanford University.

Currently Ken spends a good amount of time cultivating and advisinganumberofentrepreneurs(40-55yearsoldgroup)to grow their biotech companies.

Past recipients of CABS K. Fong Awards include:

2015: Dr. Irving Weissman of Stanford University for his pioneering research in stem cell research.

2014: Dr. Ge Li of Wuxi Apptec for creating and shaping the CRO business model in China and Dr. Hing L. Sham, formerly of Abbott for his leading role in the discovery of life-saving HIV protease inhibitors, ritonavir and Iopinavir.

2013: Dr. Peter Hirth of Plexxicon & Sugen for his pivotal role in advancing 4 successful drugs to the market and Dr. Jean Cui, formerly of Pfizer for her role as the lead designer and investigator of crizotinib, a successful kinase inhibiting drug used in personalized medicine.


37

CABS Activities 2015 – 2016

Science & Technology Programs

Business & Career Development

International Collaboration

Social Life

Mem

bership


38

CABS Investor Forum 2016January, 13th, 2016, San Francisco, CA

•J.P.MorganHealthcareConferenceisheldinSanFranciscoin January every year, and we saw a tripling in the number ofattendeesfromChinain2015.

• CABSservingasabridgeforthelifesciencescommunitiesacross the Pacific was uniquely positioned to host an investment forum at the same time.

• OurinauguralCABSInvestorForumorganizedincollaboration with ChinaBio and Morrison & Foerster discussed China-focused early-stage investments from the perspective of intellectual property, venture capital firms, traditional Chinese pharmaceutical companies, private investors, and entrepreneurs.

• Ourforumfeaturedfiveesteemedpanelistsfromabroadspectrum of interest groups and moderated by Greg Scott, Founder, ChinaBio® Group:

•DrNisaLeung,ManagingPartner,QimingVenture•DrMasoodTayebi,Investor,BridgewestBusinessGroup•DrMikeLiu,HeadGlobalBD,HengruiPharma•DrWeiZheng,Co-founder,SuzhouConnect•DrJanetXiao,Partner,Morrison&Foerster

•Morethan120peopleattendedtheevent.Theindepthdiscussion, broad range of information shared, and energizing panelists provided CABS a successful basis for many future CABS Investor Forums to come.

Highlight of Past Events with our Partners

• CABS Investor Forum 2016

• Naturejobs Career Expo

• BioSciKin Competition for Life

Sciences Startup


39

Naturejobs Career Expo-San FranciscoApril 27, 2016; San Francisco, CA

•NaturejobsCareerExpoisaglobalcareerfairandconference for the science community across the UK, US and Germany.

• SanFranciscohostedthefirsttheNaturejobsCareerExpoin 2016

• Actingasanambassador,CABSendorsedandactivelypromoted Naturejobs Career Expo to scientists in our community.

• Over20exhibitorsincludingGenentech,Merck,FredHutchinson Cancer Research Center were present.

• Theconferenceandworkshopsessionsaimedtoprovidedelegates with practical advice and inspiration to help achieve their career goals. The topics covered career in academia, career in industry, science communication, etc.

• Thisfreeone-dayeventalsoofferedtheattendeesachancetobenefitfromone-to-oneresumechecking;networkwithleadingscientificinstitutions;learnhowtoenhanceyouremployability;andmaximizethecareerprospects.


40

BioSciKin (BSK) International Start-Up Competition for Life Sciences Companies San Francisco Bay Area PreliminaryApril 7, 2016; Stanford University

•CABSwastheleadorganizerfortheSanFranciscopreliminary,incollaboration with the Association of Chinese Students and Scholars at Stanford (ACSSS) and the California Life Sciences Institute (CLSI)

• WeareproudforcontributingtothesuccessoftheSanFranciscoBayArea Preliminary, which was one of the largest US-China Life Sciences business plan competitions to date.

• BSK,aChina-basedopeninvestmentandincubationplatform,incollaboration with Simcere Pharmaceutical Group and global venture capital firms were the sponsors for this international competition.

• Thepreliminariesofthiscompetitionwereheldin8cities,includingSanFranciscoBayAreaandBostonandover150businessplansfromUScompanies were received.

• 70applicationsweresubmittedforthepreliminaryatSanFranciscoBayArea and 10 applicants were selected to present at the preliminary held on April 7 at Stanford University.

• Thiseventwasover-subscribedwithover150peopleattending.• ThewinneroftheSanFranciscoBayAreaPreliminarywasFibralign

Corporation, a South San Francisco based company, and was awarded $30,000 in non-dilutive funding. The runner-up was Denovo, a San Diego-based company. Both companies received a paid round-trip to Shanghai to participate in the final competition.

• CABSplayedapivotalroleinsolicitingbusinessplans,eventpromotionas well as on-site management of the San Francisco Bay Area Preliminary.


41

The CABS Science Technology Committee fosters scientific exchanges in the life science industry. Each year, the committee organizes a series of seminars to discuss the current trends and cutting edge technologies in life sciences, often focusing on a specific approach or technology throughout the year. Members of CABS not only benefit through the seminars but also have the opportunity to interact directly with the speakers who are usually veterans, well-known scholars, or entrepreneurs. In addition, the seminar series also provide members the opportunity to connect with other professionals with diverse areas of specialization, which could lead to unexpected insights. Detailed information for these and other events can be viewed at the CABS homepage (www.cabsweb.org).

2016 Upcoming EventsOrgan therapies and stem cell: June 2016

Drug development: September 2016

Omics and big data: October 2016

Past EventsNew Frontiers in Peripheral MonitoringSeptember,2015,Burlingame,CA

Liquid biopsies have now emerged as promising tools that are safer and cheaper than traditional tissue biopsies to survey health and disease state. For the first time, we are now able to

obtain a wealth of information from blood and urine derived circulating DNA fragments that could revolutionize research and patient care. This workshop was led by founders and leaders of companies which have pioneered the frontiers of peripheral monitoring. We discussed the science and applications behind these novel technologies as well as the trials and tribulations of building a life science start-up.

Event SpeakersChristine Fu, Scientist, Fluxion BiosciencesPaul Tang, CTO, AccuraGenMojgan Haddad, Sr. Director, Bioinformatics and Analytics, Health TellJohn Waldeisen, Co-founder and CEO, DiAssessNikolay Sergeev, R & D leader, Natera Perspective in Single Cell Genomics-by Professor Stephen QuakeFebruary, 2016, Palo Alto, CA

This event was a collaboration between CABS and CLIPSS (Chinese Life-science Postdocs and Students At Stanford). In this workshop, Prof. Quake shared his perspectives on the emerging single-cell genomics. Advances in whole-genome and whole-transcriptome amplification have permitted the sequencing of the minute amounts of DNA and RNA present in a single cell. Single-cell approaches stand poised to revolutionize our capacity to understand the scale of genomic, epigenomic, and transcriptomic diversity that occurs during the lifetime of an individual organism. Single-cell techniques, ranging from flow cytometry and microfluidics to PCR and sequencing, are used to understand the cellular composition of complex tissues, find new microbial species, and perform genome-wide haplotyping.

Science & Technology Programs2015 – 2016 Co-Chairs: Ann Mongan, Ph.D. and Jiwen (Jim) Liu, Ph.D.2014 – 2015 Co-Chairs: Jianlong Lou, M.D., Ph.D. and Jessica Sun, Ph.D.


42

Recent innovations in drug discoveryApril 23, 2014, Burlingame, CA

Speakers in this workshop described elegant innovations in chemistry, which has opened new avenues in drug discovery. In particular, Dr. YK Zhang presented benzoxaborole chemistryinthesearchforantimalarialagents;benzoxaborolestructure has not been widely used in drug discovery previously. Dr. Henry Johnson presented discovery efforts towards immunoproteasome, which recently has become exciting targets with the approval of bortezomib and carfilzomib as anticancer treatments. Lastly, Dr. Leping Li presented innovations in discovering new chemical space for generating successful IND candidates targeting hepatitis C virus(HCV)non-structural5A(NS5A)protein.

Event SpeakersDr. YK Zhang, Discovery of Benzoxaborole Antimalarial Agents, Research Leader of AnacorDr. Henry Johnson, Targeting the Immunoproteasome, Principal Scientist of Kezar BiotheapeuticsDr.LepingLi,ExpandingtheHCVInfectionTreatmentOptionsthroughChemistry,VPofAssemblyBiosciences

Business & Career Development2015 – 2016 Co-ChairsJessica Sun, Ph.D. and Alex J. Zhang, Ph.D.2014 – 2015 Co-ChairsCheni Kwok, Ph.D., CLP and Sean Xiang Wu, Ph.D.

Our mission:•Toservethebusinessandcareerdevelopmentneedsof

our members and the San Francisco Bay Area life sciences community

•Toprovideourmemberswithinteractive,informativeplatforms and networks to launch, to transition, or to advance their careers in the life sciences industry

•Toenableoursponsorstoeffectivelyrecruittalent,management team, and innovative projects

Upcoming EventsEntrepreneur Club (E-Club) will continue provide a network among existing and future entrepreneurs through workshops and casual lunch meetings.

BCD will organize workshops on interdisciplinary collaboration, to foster the collaboration between biosciences and technology fields.

BCD will co-organize job fairs and career development workshops to provide job seekers a way to explore career opportunities and to be better informed about the job market.

Past EventsCABS E-Club Event - Modern Seafarers: Navigating Life Sciences Investments and Entrepreneurships between US and the Far East 2015-06-10,PaloAlto,CA

The life sciences sector reached new heights in performance in the IPO market as well as M&A in 2014. Global life sciences M&A deal value and volume surged to record high since 2000. What are the opportunities and challenges for entrepreneurs who wish to venture to the Far East? What are the investors looking for in funding new companies that operate on both sides of the Pacific Ocean? When will the trade winds change and what can we do as entrepreneurs and investors to catch them? Our modern seafarers will share their expertise and guide our entrepreneurs to navigating the Orient.

Modern Seafarers:Anula Jayasuriya, MD., Ph.D., M.B.A., Co-founder of Evolvence India Life Sciences FundCheng Liu, Ph.D., Founder & CEO, Eureka TherapeuticsJonathan Norris, JD, Managing Director, Healthcare Practice, SiliconValleyBankMohan Uttarwar, Co-Founder & CEO, iNDx LifeCare, Inc.JimmyWei,Ph.D.,M.B.A.,VenturePartner,KPCB,China


43

Moderators:Glen Sato, JD, M.B.A., Partner, Cooley Cheni Kwok, Ph.D., CLP, Managing Partner, Linear Dream

Co-hosted CABS Investor Forum 2016 January 13, 2016, San Francisco, CA

Biotech innovation goes hand-in-hand with investment. As the demand for novel products reaches a new height on both sides of the Pacific Ocean, we would like to invite you to participate in our first CABS Investor Forum featuring panelists from a broad spectrum of investment groups. We will discuss China- focused early-stage investments from the perspective of intellectual property, venture capital firms, traditional Chinese pharmaceutical companies, private investors, and entrepreneurs.

PanelistNisaLeung,ManagingPartner,QimingVentureMasood Tayebi, Investor, Bridgewest Business GroupMike Liu, Head Global BD, Hengrui Pharma Wei Zheng, Co-founder, Suzhou ConnectJanet Xiao, Partner, Morrison & FoersterGreg Scott, Founder, ChinaBio® Group (Moderator)

Career Advisory Network (CAN) ProgramIn keeping with its mission of engendering professional interaction and development within the biotech/pharma industry, the Chinese-American BioPharmaceutical Society (CABS) is offering a free mentoring program, Career Advisory Network (CAN), to help advance career goals of its active members.

CAN is a six-month program with 1:1 mentoring meetings and group network sessions. We have lined up an exceptional group of mentors with diverse expertise and experiences encompassing pharmaceutical R&D, biotechnology development, project management, business development, patent law, management consulting, venture capital and entrepreneurs. Once matched, mentees will meet with their mentor monthly to discuss specific career-building topics. As part of the process, participants will create a personal strategic plan for identifying ways to achieve career goals.CAN program has been successfully held for the past six years and received many positive feedbacks. It is an excellent opportunity to interact and network with a diverse group of people in academia and industry in a supportive and informal setting. 2016 CAN program continues to provide our members an interactive relationship with mentors discussing personalized career issues such as work life balance, transition alternative career path, entrepreneurship in US and China, workplace interpersonal skills and managerial skills.

2015 Mentor-Mentee Programs: Brunch Mix SeptemberandOctober,2015;BayArea,CA

2015 CAN Program Graduation & Panel Discussion: Management and Leadership in Industry November14,2015,Burlingame,CA

CongratulationstoCANProgramClassof2015!Thebiotechand pharmaceutical companies are operating in an era of transformation. Soft skills and the ability to work across disciplines have become prerequisite for career advancement. The technically skilled professionals must develop more management and business skills to capture these opportunities. Three successful biotech professionals shared their experience on leadership, communication, collaboration skills,time-,self-,project-management;andanswerquestionsabout career development.

PanelistShichang Miao, Ph.D., Senior Director, ChemoCentryx IncKedan Lin, Ph.D. Senior Scientist and Therapeutic Area Leader, GenentechWentao Zhang, Ph. D., Founder of Quintara Discovery


44

2016 CAN Program Kickoff March 26, 2016, Burlingame, CA Naturejobs Career Expo - San FranciscoDate: April 27, 2016 , San Francisco, CA

The Naturejobs Career Expo is the global career fair and conference for the science community from Naturejobs and Natureconferences. The Naturejobs Career Expo 2016, hosted for the first time in San Francisco, offers talented researchers an excellent opportunity to meet a diverse selection of national and international employers from academic institutions and scientific industries, such as pharmaceutical organizations, digital technology companies, science publishing and more

•Attendallconferencesandworkshopsforfree•Meetemployersface-to-face•Benefitfromone-to-oneresumechecking•Networkwithleadingscientificinstitutions•Learnhowtoenhanceyouremployability•Maximizeyourcareerprospects

As an ambassador, CABS endorses and actively promotes the Naturejobs Career Expo to scientists in our community.

International Collaboration2015 – 2016 Co-ChairsYan Wang, Ph.D. and Wei Zhang, Ph.D.2014 – 2015 Co-ChairsYan Wang, Ph.D. and Zhenhai Shen, Ph.D., M.B.A.

The CABS International Collaboration Committee (ICC) strives to promote international collaborations with various life sciences organizations and serves as a bridge that connects our members to life sciences communities in the Pacific Rimcountries.InOctober2015wearrangedourannualCABSentrepreneurdelegationtriptoChina.FromMay2015toApril 2016, we hosted multiple Bay Area events to facilitate networking and partnership opportunities including CABS Investor Forum and BioSciKin Contest for Life Science Start-ups.

Planned EventsWe will host a partnering event at the day of BioPacific Conference and the day after for conference sponsors including China Science Parks and pharmaceutical companies to interact with CABS members for talent recruitment and project collaboration.

We will organize 2016 CABS member China trip in fall to introduce CABS members and their projects to the Science Parks, pharmaceutical companies and investment firms in China to seek project collaboration and job positions.We will continue to host various events to facilitate the networking and partnership opportunities, and promote international collaborations in the Pacific Rim countries.Past Events

2015 CABS Delegation to Cities and Science Parks in China October7toOctober14,2015

Dr.YanWang,Co-chairof2015-2016ICC,incollaborationwith our executive committee, organized a delegation of CABS life sciences entrepreneurs to attend the “Entrepreneur Ningbo Trip” event and to visit science parks and life sciences companies in Ningbo and Hangzhou. The key objectives of this delegation were:•Topromoteinternationallifesciencescollaborations

between US and China2015 CABS Delegation to China, meeting with BioClub and Zibo Nation-al High-Tech Industrial Development Zone at BioClub in Hangzhou


45

•Toenableourentrepreneurialmemberstoevaluateopportunities to establish or to expand their operations in China;toenableCABSmemberstobeabletofindsuitablejob position in China pharmaceutical company

•TogaininsightfromsuccessfulChinese-basedlifesciencescompanies

•ToestablishnewCABSstrategiccollaborationswithscienceparks and local governments in China

•ToraiseawarenessofCABSasamajorChinese-Americanlifesciences professional organization

•Toprovideaplatformtosharethelatesttrendsofresearchand development in US with Chinese life sciences companies/organizations and to facilitate the recruitment of US life sciences talents, entrepreneurs and professionals to China

Discussion about Drug Discovery and Development Opportunities in ChinaMay10,2015;SiliconValley,CA

We hosted an informal but in-depth discussions with Dr. JimmyZhang,VPofTransactionsatJohnson&JohnsonInnovation. Dr. Zhang talked about drug discovery and development opportunities in China, as well as how to take advantage of the opportunities and participate in the process. Audiences are very interested in the topic and had a great discussion.

Introduction of CITIC Private Equity Funds Management Co., Ltd. 中信产业基金投资座谈会June17,2015;SiliconValley,CA

The CITIC delegation visited the Bay Area to seek suitable biotech companies and projects to fund and collaborate. Several CABS members presented their business plans at the meeting and got feedback. Meanwhile, the audiences had the opportunity to learn about the business environment in China introduced by CITIC.

Networking with Qilu Pharmaceutical 齐鲁制药对接洽谈会September4,2015;SiliconValley,CA

Senior executives of Qilu Pharmaceutical visited the Bay Area to look for talents to join Qilu in Jinan, Shangdong province, and therapeutic project and platform for collaboration in the areas of biologics drug discovery and process development, small molecule formulation development, and innovative or me-better target drugs. CABS members are enthusiastic about the opportunities. The meeting included several presentations of CABS members’ projects as well as the introduction of the need from Qilu Pharmaceutical.

2016 BioSciKin contest for life science start-ups at Stanford University


46

Real-time Video Meeting of BioClub Medical Device ConferenceNovember11,2015;SiliconValley,CA

Bioclub hosted a medical device conference in Hangzhou where there were over 1000 attendees including executives, investors and entrepreneurs. In order to promote the communication and for CABS members to get familiar with the advancement in medical device area in China, we set up avideomeetinginSiliconValleytowatchtheconferenceinreal-time. Afterwards, we discussed about innovation and entrepreneurship. People are very enthusiastic about sharing ideas and visions.

Tianjin Asymchem Company Recruitment Event December15,2015;Berkeley,CA

We organized a talent recruitment event for Asymchem Laboratories Inc. in Tianjin, one of the world’s leading contract manufacturing organizations providing the pharmaceutical industry with APIs and API intermediates. At the recruitment event at Berkeley, there were company introduction, questions and answers, and one-on-one interviews. People show interest to go back to China to work. It was also a great opportunity for people to get to be familiar with the working environment in China. CABS Investor Forum 2016January13,2016;SanFrancisco,CA

The president of CABS Jiangwen Majeti led ICC and BCD committee to organize the first investor forum of CABS. The forum was held in conjunction with JP Morgan Healthcare Investment Conference in 2016. The forum discussed China-focused early-stage investments from the perspective of intellectual property, venture capital firms, traditional Chinese pharmaceutical companies, private investors, and entrepreneurs.Morethan150peopleattendedthisforum.We invited featuring panelists from a broad spectrum of biotech-focused investment groups. They are: Nisa Leung, ManagingPartner,QimingVenture;MasoodTayebi,Investor,BridgewestBusinessGroup;MikeLiu,HeadGlobalBD,HengruiPharma;WeiZheng,Co-founder,SuzhouConnect;JanetXiao,Partner,Morrison&Foerster;GregScott,Founder,ChinaBio® Group (Moderator)

Talent recruiting and project collaboration event with Chia Tai Tianqing Pharmaceutical Group正大天晴药业集团推介会February28,2016;SiliconValley,CA

CABS helped Chia Tai Tianqing Pharmaceutical Group (CTTQ) to organize a talent recruiting and project collaboration event. Dr. Tong Xu, Chief Representative – North America, introduced thecompany.Dr.LingYang,VicePresidentofProjectManagement, shared the vision on project collaboration. Mr. JieZhang,VicePresident,presentedthekeypositionstheyare recruiting. Afterwards, there were small group meetings on project presentation and job interview. CABS members were enthusiastic about these opportunities. CTTQ is the leading pharmaceutical company with integrated R & D, manufacturing, distribution, marketing, and sales in China with7500employeescurrently.Itisthemarketleaderindrugs treating liver diseases in China since mid-1990.

BioSciKin Competition for Life Sciences Start-Ups April7,2016;SiliconValley,CA

Dr.YanWang,Co-chairof2015-2016ICC,ledtheextensiveefforts to organize 2016 BioSciKin (BSK) Life Science Start-ups Contest in San Francisco Bay Area. This contest, mainly sponsored by BSK and Simcere Pharmaceutical Group, has six preliminaries in China and two in the US including San Francisco and Boston. This is the first time that China pharma and venture host such an event across China and the US in the lifesciencespace.BSKreceivedover150applicationsfromSan Francisco and Boston start-ups, with over 70 for the Bay Area competition. Among the 70 start-ups, 10 were selected to present on the stage on April 7 at Stanford University. The top two winners were invited to the final contest in June in Shanghai. The first place winner, South San Francisco-based Fibralign Corporation, was awarded $30,000 prize and the second place winner, San Diego-based Denovo Biopharma, receivedafreeround-triptoShanghaiforthefinal.Over150attendees witnessed the great success of the event. Inadditiontotheroadshowofthestart-ups,Dr.LinWu,VicePresident of Development for the Sequencing Business Unit of Roche Diagnostics, gave the keynote address on non-invasive liquid biopsy for cancer patients. The event also included remarks from Dr. Penghui Xu, Science Consul from Consulate General of the People’s Republic of China in San Francisco, and Dr. Cheni Kwok, President-elect of CABS. The contest was organized by CABS, the Association of Chinese Students and Scholars at Stanford (ACSSS) and the California Life Sciences Institute (CLSI).


47

Social Life2015 – 2016 Co-ChairsSihong Zhou, and Ken Zhang, Ph.D.2014 – 2015 Co-ChairsBo Lian, Ph.D. and Jian Zhang, Ph.D.

The Social Life Committee (SLC) Statement

The Social Life Committee (SLC) is dedicated to serving our members with high quality indoor and outdoor activities. Within the CABS community, SLC intends to provide the opportunity to make connection, build relationship and enhancetheinteraction;toenrichandimprovelifequalitybysharing knowledge, organizing fun events, and co-creating memorable experience.

The key objectives of CABS Social Life Committee are: To serve our CABS members through hosting seminar & talks, and organizing social activities.

To provide networking and social interaction platform for CABS family.

To create opportunity for friendship and professional development.

To promote healthy and positive life style for our CABS community.

Coming Events:• Group hiking and outdoor recreational activities• Taste of the American culture

• Financial management and asset protection related seminars• CABS Summer BBQ 2016• Seminar about family relationship and health issues• Green card and college application

Past EventsAnnual Summer BBQ Networking PicnicAugust8,2015,FosterCity,CA

Over250CABSmembers,familiesandfriendsattendedthiswell-organized party. In addition to the delicious food, people also enjoyed mingling with friends, playing sports and lots ofotheractivities.Wethanktheparticipantsforthesupport;wecongratulatethoseonwinningtheluckydraws;weonceagain thank our volunteers for the tremendous help. And we also look forward to more and more people participating in our future events and activities!

2016 CABS Chinese New Year PartyJanuary 31st, 2016, Foster City, CA

Happy Chinese New Year!!! CABS kicked off the Year of the Monkey with exciting CABS traditional New Year Festivities! More than 200 attendees, including volunteers and performers, were present.

Activities included singing and dancing, Beijing opera, other live musical entertainment, spring festival couplets and conundrum, and much more! Audience enjoyed the high quality of music and dancing performance. There were games for children and lucky draws for everybody! And the top lucky raffle winner went home with a new Apple iPad!!! People reconnected with old friends and made new ones while having fun celebrating Chinese New Year 2016 together!


48

CABS SEMINAR: DIAGNOSIS AND TREATMENT OF ACUTE HEART ATTACK*January 23, 2016, Foster City, CA

Heart attack remains a leading cause of death in US and worldwide. Heart attack can result in critical reduction of blood and oxygen supply to heart for an extended period, which can cause irreversible heart muscle damage or death. It is important to control or eliminate the risk factors of heart attack. Also, it is critical to recognize the symptoms of a possible heart attack and take the appropriate action.

At the seminar, audience gained a better understanding of this disease, which is your first step to fully embracing self-care. The speaker, Dr. Lin, also introduced some tips to help develop an effective self-care plan.

*Co-hosted with Silicon Valley Sichuan University Alumni Association (SVSUAA)

Membership2015 – 2016 Co-ChairsLiping Meng, Ph.D. and Yonghua Pan, Ph.D.2014-2015 Co-ChairsYang Tian, Ph.D. and Liping Meng, Ph.D.

IntroductionThe mission of the Membership Committee is to support all major CABS events registration and check-in process, as well as to promote the non-profitable CABS membership.

Past EventsCABS Investor Forum 2016January 13, 2016, San Francisco, CA

CABS, ChinaBio Group and Morrison & Foerster co-hosted the first CABS investor Forum featuring panelists from a broad spectrum of investment groups. Panel discussions covered China-focused early stage investments from the perspectives of intellectual property, venture capital firms, traditional Chinese pharmaceutical companies, private investors, and entrepreneurs. The panel featured Nisa Leung, Managing PartnerforQimingVenture,MasoodTayebi,InvestorfromBridgewest Business Group, Mike Liu, Head Global BD at Hengrui Pharma, Wei Zheng, Cofounder of Suzhou Connect, Janet Xiao, Partner for Morrison & Foerster, and Greg Scott, Founder of ChinaBio Group. This event attracted more than 100 Biotech Professionals from both local Bay Area and East Coast.

PanelistNisaLeungManagingPartner,QimingVentureMasood Tayebi Investor, Bridgewest Business GroupMike Liu Head Global BD, Hengrui PharmaWei Zheng Cofounder, Suzhou ConnectJanet Xiao Partner, Morrison & FoersterGreg Scott Founder, ChinaBio Group


49


50


51


52


53


54


55


56


57


58

科伦是中国十大药企之一， 2015年销售额超 390亿元，吸引了多位来自 BMS, Merck, Abbott, Regeneron, Pfizer, Biogen, Eli Lilly, JNJ，Sanofi，Boehringer Ingelheim，Teva 等优秀领军人物加盟。也在美国设立了涉及小分子和大分子领域的研发中心。中美领军职位空缺: https://kluspharmainc.gethired.com/ 生物药：杂交瘤 a，Phage Display a，培养基开发 b，细胞培养，工艺，纯化，活性测定，制剂，分析。小分子创新和仿制：计算化学，DMPK, pharmacology, toxicology，合成工艺，制剂，分析，纳米粒，脂质体，微球. 临床研究和数据管理。原料药合成和 DMF b。a中国/新泽西均有职位。b中国/新泽西时间分摊。其他为中国。薪资优厚，享受股权激励。

Email简历和职位给 [email protected]

Your premier source for heterocycles

727 Toyon Ave., Sunnyvale, CA 94086, USA 1-650-265-7852; [email protected] 1-650-504-8848 [email protected]

Cellometer Auto 2000 Cell Viability Counter

We have a wide range of instruments to accomodate all your cell counting needs. Contact us at [email protected] or learn more at www.nexcelom.com

Auto 2000 - Viability of primary cells in complex samples containing debris and red blood cells

• PBMCs• Stem Cells• Trypan Blue Viability - Cell Lines• Splenocytes• & Other Primary Cells


59

LOGO

• Product design产品设计

• Mold Design研究开发

• Material Optimization材料优化选择

• • • Prototype模型制作

• Integrity and safety testing测试

Injection molding 生产与组装

Package 包装设计

We can deliver:

The Plastic System Solutions Provider of BIOMEDevices

生物医疗塑料系统解决方案服务商

1633,Bayshore Hwy,STEBurlingame CA 94010Email:

[email protected]

www.cosmobrand.com

CONTRACT MANUFACTERSterile and Nonsterile Medical Devices

CABS Sponsorship Benefits:•AccesstolargepoolofhighprofilemembersinvariousfieldsofLifeSciences•GainexposurethroughpromotionatmanyCABSevents,variouspublicationmaterials,andInternet•Establishcloserelationsandboostbusinessopportunitieswithhundredsofotherpharmaceuticaland

biotechnology companies in both US and China•Receivetaxdeductionforyourfinancialcontribution

Contact: [email protected]


60

Conference Notes


61

Conference Notes


62

CABS Membership Benefits•ParticipateinactivitiesandeventsorganizedbyCABSandouralliances

•SignificantdiscountsforCABSeventregistrations,includingtheBioPacificConference

•ComplimentaryparticipationtomanyCABSprogramsincludingthehighlypopularCABSCareer

Advisory Network (CAN) program and the CABS Delegation to China

•Activeengagementbyvolunteeringtohelporganizingourevents

•LeadershipopportunitybyjoiningourExecutiveCouncil

Join CABS Today at: http://www.cabsweb.org/members/

CABS Sponsorship Benefits•AccesstolargepoolofhighprofilemembersinvariousfieldsofLifeSciences

•GainexposurethroughpromotionatmanyCABSevents,variouspublicationmaterials,andInternet

•Establishcloserelationsandboostbusinessopportunitieswithhundredsofotherpharmaceutical

and biotechnology companies in both US and China

•Receivetaxdeductionforyourfinancialcontribution

Sponsor our CABS events by contacting:

[email protected] or go to http://www.cabsweb.org/sponsors/ for details.

Membership Options Price

Regular Membership for 1 year $30

Regular Membership for 2 year $50

Life Time Membership $300

Sponsored Content Price

Job posting at cabsweb.org (2 months)

$100perjob(1-5jobs)

$600total(5-10jobs)

Contact [email protected] for price (>10 jobs)

Company logo at cabsweb.org (2 months) $50perlogo

Company logo in CABS weekly newsletter $50perlogopernewsletter


63

BioPacifififfifiicfififififi Conference 201618th CABS Annual ConferenceMay 7th, Saturday, 2016, 8:00AM-9:00PMSan Mateo Marriott, 1770 South Amphlett Blvd.San Mateo, CA 94402

Inaugural BioPacifififfifiic Partnering Forum 2016May 7 from 9am – 6pm onsite at the 2016 BioPacific Conference May 8 from 10am – 5pmHanqi Investment Inc. 1633 Bayshore Hwy, Burlingame, CA 94010

Who We are

•Aprofessionalnon-profitorganizationbasedintheSanFranciscoBayArea

•Over3,000membersandparticipants

•MembersfromUS,ChinaandPacificRimCountries

Our Mission

•Toservebiopharmaceuticalprofessionalswithprofessionalinterestsandpromoteprofessional interactions locally and across the Pacific

•TofosterbusinessopportunitiesandexchangesinthelifescienceindustrybetweentheU.S.andChina

•Topromotepublicawarenessofprogressanddevelopmentinthepharmaceuticaland biotechnological industry

Shooting for the StarS

Documents

Transcript of Shooting for the StarS